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Abstract 
 
Inhibition of blood coagulation via oral anticoagulant therapy is the mainstay for preventing a 
cardioembolic stroke in patients with atrial fibrillation (AF). Factor Xa inhibitors (FXaIs), 
rivaroxaban and apixaban, represent a new class of oral anticoagulants that are now widely 
prescribed in AF patients as an alternative to traditional warfarin therapy. An important 
advantage of these drugs is that routine monitoring of anticoagulation response is not 
necessary. Nevertheless, because of their mechanism of action, FXaI antithrombotic effect can 
be inferred based on the observed drug plasma concentration, with prolonged periods of 
elevated FXaI systemic exposure associated with increased risk for major bleeding.  
 
Currently, there is a paucity of data relating to observed interpatient variation in FXaI 
plasma concentrations in the post-market clinical setting. Given that the patient population that 
take FXaIs in the post-market setting may vary greatly with their co-morbidities and co-
medications from those within clinical trials, we hypothesized the systemic FXaI exposures 
achieved in these individuals may vary greatly as well, and that this interpatient variation is 
driven by patient-specific factors (physiology, disease-states, co-medications, genetics).  
 
In the first study, we determined rivaroxaban and apixaban plasma concentrations in a 
cohort of 243 AF patients during routine clinic visits, and found their measured FXaI 
concentration tended to be more variable than those observed in clinical trials.  Approximately 
12% of patients receiving rivaroxaban and 13% of patients receiving apixaban exceeded the 
predicted maximum FXaI plasma concentration observed in clinical trials.  
 
In the second study, we characterized the observed variation in FXaI concentration 
among our apixaban-treated AF cohort through regression analysis. Age and renal function 
accounted for the majority of the explained variation, while female sex and amiodarone use 
were also significant predictors of apixaban exposure. In addition, we demonstrated, for the 
first time, that 4β-hydroxycholesterol plasma concentration, as a potential biomarker for 
apixaban metabolism, was an independent predictor of interpatient variation in apixaban 
concentration.  
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Equally important, we noted in our second study, that a large proportion of the 
interpatient variation remained unaccounted for, and known common genetic variation in 
metabolizing enzymes and efflux transporters did not significantly predict apixaban 
concentration within our cohort. Therefore, we applied a custom targeted next-generation 
exome sequencing approach (PGxSeq) to potentially identify rare or patient-specific single 
nucleotide variation (SNV) in subjects with unexpectedly high drug concentration that result 
in aberrant function or expression of apixaban metabolizing enzymes or transporters. 
Following successful development and validation of PGxSeq, our exploratory analysis of 
twelve apixaban-treated AF subjects that were sequenced, revealed rare and common SNV(s) 
within the selected candidate genes. 
 
Taken together, these studies provide insight into the factors that drive variation in 
FXaI plasma concentration among AF patients in routine care, and serve as a framework for 
future investigations regarding personalization of FXaI anticoagulant therapy. 
 
 
Keywords:  
Factor Xa inhibitor, apixaban, rivaroxaban, pharmacokinetics, interpatient variation, exome 
sequencing, single nucleotide variants, pharmacogenetics 
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1.1 Blood coagulation 
Blood coagulation as part of a process known as hemostasis, is the body’s physiological response to blood vessel injury. Upon damage 
to blood vessels, a chain of pro-inflammatory and wound-healing processes begin. This includes the formation of blood clots that are 
rich in platelets, red blood cells, as well as fibrin protein, which prevents the loss of blood and allow recovery to commence. To date, 
there are two prominent models that conceptualize coagulation; the “cascade” model was proposed first in the 1960s (1, 2), while the 
“cell-based” model is more recent (3). 
 
1.1.1 Cascade model 
The cascade model depicts coagulation as a process that is directed and controlled by a series of interactions between protease zymogens, 
enzymes, and cofactors known as coagulation factors that lead to the generation of thrombin and fibrin (Figure 1-1). Although this 
model accurately depicts the interactions between individual coagulation factors, the concept that coagulation is segregated into two 
distinct pathways, the intrinsic and extrinsic pathways, provides an inadequate explanation of hemostasis as it occurs in vivo. This 
statement is supported by the observation that the factor VII protease/tissue factor complex of the extrinsic pathway is capable of 
activating factor IX of the intrinsic pathway (4). Additionally, the downstream protease, thrombin has been shown to activate factor XI 
of the intrinsic pathway (5). These findings were among the key steps that led to the understanding that the “intrinsic” and “extrinsic” 
 
 
 
19 
pathways are more interdependent than previously described. 
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Figure 1-1. Cascade model of coagulation. 
Abbreviations: TF , tissue factor 
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1.1.2 Cell-based model 
The cell-based model of blood coagulation is viewed as occurring in three successive non-exclusive phases: initiation, amplification, 
and propagation (3) 
 
 
 
1 
 
Figure 1-2). 
The initiation phase begins when tissue factor (TF, a membrane-bound protein) 
from extravascular cells become exposed to blood constituents at the injury site. 
Circulating factor VII is activated upon exposure to extravascular TF and then forms a 
complex with TF (6), which subsequently activates factors X and IX. As circulating 
platelets are exposed to the site of injury they adhere to collagen found in the extravascular 
matrix and become partially activated. A consequence of platelet activation is the granular 
secretion of partially activated factor V (7), which is a cofactor of the activated factor X 
(FXa) protease. FXa can also further activate factor V (7). Activated factor V (FVa) can 
combine with FXa on the cell surface of TF-expressing cells in the presence of calcium to 
produce a small burst of thrombin protease at the injury site (8). 
The thrombin generated during initiation amplifies the procoagulant state, by 
activating platelets and coagulation factors, thereby setting the stage for the assembly of 
procoagulant complexes on the surface of platelets to commence large-scale thrombin 
generation. Thrombin is a potent activator of platelets via the protease-activated receptors 
(PAR), where the enzyme cleaves a specific N-terminus peptide sequence from PARs to 
unmask a tethered ligand that stimulates the receptor to induce downstream procoagulant 
responses. The initial burst of thrombin also activates coagulation factors that are known 
to be part of the “intrinsic” pathway, particularly factor XI (5, 8) and factor VIII (9). These 
activated factors along with the aforementioned FVa are then recruited to the surface of 
platelets, ready for the propagation phase.  
During propagation, the initial burst of activated factor IX (FIXa) and factor X 
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(FXa) proteases combine with their respective co-factors on the surface of platelets to 
assemble tenase (FIXa/FVIIIa) and prothrombinase (factor FXa/FVa) complexes. The 
overall shift in procoagulant activity from TF-expressing cells towards platelets is 
facilitated by an increased exposure of negatively charged phospholipids (e.g., 
phosphatidylserine) on the outer membrane leaflet of platelets that is secondary to their 
activation (10). The presence of anionic phospholipids along with calcium is necessary for 
the assembly and function of coagulation factors (11).  Furthermore, given that each 
activated protease is required for the subsequent activation of a downstream protease (e.g., 
FXIa activates FIX, FIXa is incorporated into a tenase (FIXa/FVIIIa) complex which 
activates FX etc.) the close proximity of these enzymes on the platelet surface facilitates 
the rapid burst of thrombin production required for a hemostatic fibrin clot.  
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Figure 1-2. Cell-based model of coagulation.  
In the cell-based model, coagulation occurs in three subsequent non-exclusive phases: 
initiation, amplification, propagation. Trace amounts of thrombin are formed during the 
initiation phase. In the amplification phase, the thrombin produced potentiates the 
procoagulant state through cleavage activation of coagulation factors (FV, FVIII, FXI), and 
PAR which is located on the surface of platelets. During the propagation phase, the 
activated proteases and their co-factors form an assembly of coagulation complexes on the 
surface of activated platelets, where their close proximity to one another facilitates the 
large-scale thrombin generation required for a hemostatic clot. Abbreviations: PAR, 
protease-activated receptors; TF, tissue factor; vWF, von Willebrand  
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1.2 Thrombosis 
Maintaining normal blood fluidity requires a complex balancing of the procoagulant 
(thrombus producing) and anticoagulant (thrombus inhibiting) processes. An imbalance of 
these opposing processes gives rise to the potential for the formation of pathological 
thrombi within the blood vessel. Thrombi can cause local obstruction of blood flow or 
branch off and travel downstream to embolize elsewhere in the circulatory system in a 
process known as thromboembolism. Thromboembolisms that obstruct blood flow to vital 
organs such as the heart, brain, or lung can cause life-threatening complications. The 
triggering events that lead to occlusive thrombus formation are consequence of one or more 
of following: abnormal changes to the vascular wall, circulatory stasis, or a 
hypercoagulable state (Figure 1-3). This combination of events was first elucidated by 
Rudolf Virchow in the 1700’s and is known as Virchow’s “triad” (12).  
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Figure 1-3. Virchow’s triad. 
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1.2.1 Venous thrombosis 
The vascular environment plays an important role in the type of thrombus formed, as well 
as in determining the associated clinical complications. Venous thrombosis most 
commonly occurs within the deep veins of the leg where it is known as deep venous 
thrombosis (DVT). It can be caused by stasis in venous circulation (e.g. prolonged bedrest), 
as well as impaired local regulation of anticoagulant processes (e.g. protein C and S 
deficiency). Clinical complications of DVT include edema and congestion in the vascular 
beds distal to an obstruction; however, DVT is most problematic for its capacity to 
originate pulmonary embolisms that cause death.  
 
1.2.2 Arterial thrombosis 
Typically, arterial thrombosis occurs following the rupture of an atherosclerotic plaque in 
the presence of fast moving blood, with thrombus formation highly dependent on platelets. 
A notable exception to this occurs in the case of atrial fibrillation (AF), since AF-related 
thrombi are formed under low blood flow and are dependent upon the activation of the 
coagulation cascade. The major complications of arterial thrombosis include the 
obstruction of coronary and cerebral arteries causing cardiac ischemia (angina, myocardial 
infarction) and ischemic stroke, respectively. 
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1.3 Thrombogenesis in the setting of atrial fibrillation 
Atrial fibrillation is the most common pathological cardiac arrhythmia and is most 
prevalent among the elderly (13). In 2010, the estimated number of men and women 
affected by AF worldwide were 20.9 and 12.6 million, respectively (14). Cardiogenic 
cerebral thromboembolisms resulting in ischemic stroke have long been strongly 
associated with AF, dating back to the Framingham study in the early 1990s, which 
reported a 5-fold greater incidence of stroke in those with AF as compared with disease-
free subjects (13). 
Cardiogenic emboli in the setting of AF are also thought to be triggered by the 
fulfillment of Virchow’s triad (15). During episodes of AF, the atrial myocardial tissue 
experiences uncoordinated activation leading to ineffective contractions and reduced 
cardiac flow, which promotes blood stasis, particularly in the left atrium and left atrial 
appendage (LAA). The LAA, a long narrow inlet within the left atrium, is believed to be a 
major source of cardiogenic emboli leading to ischemic stroke (16, 17). In addition to 
stasis, structural changes in the form of atrial dilation and endocardial dysfunction are also 
attributed to AF (16, 18-20). Finally, there is evidence of abnormal changes in blood 
constituents that are indicative of a hypercoagulable state (15), thereby fulfilling Virchow’s 
triad. For example, patients with AF exhibit elevated levels of the fibrin degradation 
product, D-dimer (21, 22), and von-Willebrand factor (23, 24) compared to patients 
without AF. Inflammatory cytokines (e.g. high-sensitivity C-reactive protein (25) and 
interleukin 6 (26)) as well as growth factors (e.g. vascular endothelial growth factor (23, 
27)) that stimulate TF production (28, 29), have been also found to be elevated in patients 
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with AF, suggesting that inflammation as well as enhanced growth factors could also be 
contributing to the hypercoaguable state in AF patients. 
 
1.4 Stroke prevention in patients with atrial fibrillation 
Oral anticoagulants (OACs) are the recommended preventative therapy for reducing stroke 
risk in patients with AF (30-32). As a class, anticoagulants function by hindering fibrin 
formation either through indirect or direct inhibition of coagulation factor(s). Compared to 
antiplatelets, which inhibit platelet activation or aggregation, OACs are more effective at 
reducing stroke and mortality incidence in AF patients (33, 34). The effectiveness of OACs 
over antiplatelets can be attributed to the fibrin-rich, low-platelet nature of AF-related 
thrombi (35). 
 
1.4.1 Therapeutic interventions 
The recommendation for use of OACs in the setting of AF is based on a patient’s assessed 
stroke risk (31), which is increased by the presence of additional clinical factors such as 
advanced age, hypertension, and diabetes mellitus (36). Therefore, prediction formulas 
such as CHADS2 (36) and CHA2DS2-VASc (37) (defined in Table 1-1  and Table 1-2) 
have been developed to stratify patients with AF in order to identify those that might benefit 
from receiving anticoagulant therapy. For example, according to the 2016 Canadian 
Cardiovascular Society guidelines for management of AF patients, OAC therapy is 
recommended for AF patients that are ≥ 65 years of age or for younger patients with 
CHADS2  score ≥ 1(38). 
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Table 1-1. CHADS2 stroke risk stratification schema for patients with atrial 
fibrillation 
 
CHADS2 Points† 
C Congestive heart failure 1 
H Hypertension 1 
A Age ≥75 1 
D Diabetes mellitus 1 
S Prior stroke or transient ischemic attack 2 
† Based on the number of risk factors an individual possesses these points are summed to 
calculate their CHADS2 score value.  
 
 
 
 
 
Table 1-2. CHA2DS2-VASc stroke risk stratification schema for patients with atrial 
fibrillation. 
 
CHA2DS2VASc Points† 
C Congestive heart failure (Left ventricular ejection fraction ≤40%) 1 
H Hypertension 1 
A Age ≥75 years 2 
D Diabetes mellitus 1 
S Prior stroke/transient ischemic attack/thromboembolism 2 
V Vascular disease 1 
A Age 64-74 years 1 
S Female sex 1 
†Based on the number of risk factors an individual possesses these  points are summed to 
calculate their CHA2DS2VASc score value. 
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1.4.2 Warfarin 
Warfarin was the first OAC widely used as a prophylactic for stroke prevention in patients 
with AF. Its use is associated with a 64% reduction in stroke incidence compared to placebo 
(39). Warfarin indirectly depletes the biologically active supply of key vitamin K-
dependent clotting factors (II, VII, IX, X, protein C and S) through its action as a Vitamin 
K epoxide reductase antagonist. While warfarin is highly effective at reducing stroke risk, 
major bleeding remains a significant safety concern with its long-term use.  
 
1.4.3 Direct-acting oral anticoagulants 
1.4.3.1 Phase III clinical trial data 
The advent of the next generation of OACs was enabled by the discovery of the crystal 
structures of the key coagulation factors thrombin (40) and factor Xa (41). Small molecule 
inhibitors called direct-acting oral anticoagulants (DOACs) were developed to directly 
target these rate limiting enzymes. Four pivotal randomized control trials (RCT) that 
compared the efficacy and safety outcomes of each of these drugs to warfarin were 
published between 2009 and 2013 (42-45). Dabigatran, the first thrombin inhibitor to be 
approved, was found to be equally efficacious as warfarin for prevention of stroke and 
systemic embolism (SSE) in AF patients and had comparable adverse bleeding rates. This 
was followed by the approval of the factor Xa inhibitors rivaroxaban, apixaban, and 
edoxaban. Compared to warfarin, apixaban was superior in reducing SSE events and had 
lower rates of bleeding, while rivaroxaban and edoxaban had comparable rates of SSE. The 
rates of bleeding were lower for edoxaban when compared to warfarin, however were 
comparable between rivaroxaban and warfarin. Further meta-analysis of pooled data from 
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all four trials found that the greatest benefit of the DOACs class was a substantially reduced 
rate of intracranial hemorrhage, which is a potentially fatal complication of OAC treatment, 
while the greatest detriment was a higher rate of gastrointestinal bleeding (46). Thus 
overall, RCT data concluded that DOACs offer a favourable balance of safety and efficacy 
compared to warfarin. 
 
1.4.3.2 Dosing and administration 
The initial dose selection is straightforward for DOACs. Patients are given either the 
standard dose or a reduced dose based upon meeting specific clinical criteria such as renal 
impairment, low body weight, and interacting medications. The recommended dose of 
dabigatran is 150 mg twice daily or 110 mg twice daily if patients are aged ≥ 80 years (47). 
Rivaroxaban is to be taken with food at a standard dose of 20 mg once daily, unless patients 
have moderate renal impairment with an estimated creatinine clearance ranging between 
30 and 49 mL/min (48). The recommended dosage for apixaban is 5 mg twice daily, or 2.5-
mg twice daily for patients fulfilling two of the three following clinical criteria: age ≥ 80 
years, serum creatinine value ≥ 133 mmol/L, and weight ≥ 60 kg (49). Edoxaban has a 
recommended dose of 60 mg once daily or 30 mg once daily in patients with one or more 
of the following clinical criteria: moderate renal impairment as defined above, body weight 
≤ 60 kg, or a taking an interacting medication such as a P-glycoprotein inhibitor (50). 
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1.5 Clinical and genetic determinants of optimal oral 
anticoagulant therapy 
 
Given the mechanisms by which OACs elicit their effects, differences in drug response are 
a concern for adverse reactions. The efficacy of OACs in reducing stroke or systemic 
embolic events is counter-weighed by the risk of major bleeding events, including bleeds 
that result in death by exsanguination, symptomatic bleeding into critical sites or organs  
(e.g. intracranial or gastrointestinal), a hemoglobin drop ≥2 g/dL, or the necessity of a blood 
transfusion. Therefore, achieving balanced anticoagulation is critical for maximizing the 
safety and efficacy of OACs. 
 
1.5.1 Warfarin 
The earliest attempts at long-term warfarin use were complicated by unacceptably high 
bleeding rates (51, 52). Subsequently, it was found that lower intensity anticoagulation 
regimens monitored carefully by hemostatic testing using the prothrombin time (PT) test  
could be as effective (Figure 1-4), but safer than high-intensity regimens (53, 54), 
improving the safety of warfarin use in patients. PT test measures the clotting tendency of 
blood determined as the time required for a blood sample to clot, specifically evaluating 
the extrinsic pathway of coagulation (factors I, II, V, VII, X), where warfarin treated 
samples would have longer PT times, then untreated samples. In the 1980s, prothrombin 
international normalized ratio (INR) was introduced by the World Health Organization 
(WHO), which globally standardized the PT test for assessing anticoagulation. Today, 
warfarin dosing is based on achieving a target INR value of between 2.0 and 3.0 for AF 
patients (54). However, in order to achieve this therapeutic range in patients, prescribers 
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must accommodate an up to 20-fold variation in warfarin dose that exists between 
individuals. Aside from demographic (age, sex, weight) and clinical variables (renal or 
hepatic disease, dietary, interacting medication), there is a significant contribution from 
genetic variation within the proteins involved in warfarin’s metabolic and/or drug response 
pathway that complicate achieving a therapeutic warfarin dose. 
 
 
 
Figure 1-4. International normalized ratio and prothrombin time 
International normalized ratio (INR) is expressed as the relationship between the 
prothrombin time of a warfarin-treated blood sample over the prothrombin of an untreated 
sample. INR values between 2.0 and 3.0 provide greatest therapeutic benefit. INR values 
less than 2 and greater than 4 are associated with increased risk of stroke and hemorrhage, 
respectively.  
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1.5.1.1 Mechanistic determinants of warfarin dose response 
Warfarin is administered as a racemic mixture of two active enantiomers (R- and S- 
isomers) that are rapidly absorbed from the gastrointestinal tract at high oral bioavailability 
(product monograph). After absorption, the drug accumulates in the liver and functions as 
an inhibitor of the Vitamin K epoxide reductase enzyme (VKORC1) with the S isomer as 
the stronger antagonist (55, 56). Warfarin is almost entirely excreted through the urine in 
the metabolite form (57). The two enantiomers undergo metabolism by different 
cytochrome P450 (CYP) enzymes (58), with the inhibition of S-warfarin metabolism being 
of greater clinical relevance. 
The more potent enantiomer, S-warfarin, is metabolized by CYP2C9 into its 
inactive form S-7-hydroxywarfarin (58). However, the CYP2C9 gene has several genetic 
variations, of which the CYP2C9*2 and CYP2C9*3 polymorphisms show decreased 
enzymatic hydroxylation of S-warfarin in vitro (59, 60). The allele frequencies for 
CYP2C9*2 (c.430 C>T) and CYP2C9*3 (c.1075 A>C) are approximately 12.5% and 8.5% 
in Caucasian populations (61), although these numbers vary based on ancestry. Genotyping 
for these alleles have demonstrated that variant carriers have reduced S-warfarin clearance 
(57), reduced warfarin dose requirements (62, 63), and increased risk of over 
anticoagulation. In a meta-analysis of nine studies including 2275 patients, variant carriers 
of CYP2C9*2 and CYP2C9*3 had an average dose reduction of 17% and 37%, 
respectively, compared to CYP2C9*1 (wildtype) (64). 
Warfarin elicits its anticoagulant effect on the enzyme VKORC1, which is involved 
in the cyclic interconversion of Vitamin K (Figure 1-5) as part of the physiological 
recycling of Vitamin K1 dihydroquinone (65). Vitamin K1 dihydroquinone (VKH2) is an 
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essential cofactor in the post-translation carboxylation of N-terminal glutamate residues on 
Vitamin-K dependent coagulation proteins (65). These proteins, which include coagulation 
factors II, VII, IX, and X as well as anticoagulant factors protein C and protein S, require 
carboxylation to render them biologically active (65). Gamma-glutamyl carboxylase is 
responsible for carrying out this reaction using VKH2, CO2, and O2. VKH2 is converted to 
Vitamin K epoxide as a product of the reaction. VKORC1 is then responsible for the 
chemical reduction of vitamin K epoxide to vitamin K1, an intermediate that is further 
reduced to vitamin K1 dihydroquinone (65). Therefore, by inhibiting VKORC1, warfarin 
impedes the vitamin K cycle and depletes the biologically active supply of vitamin K 
dependent coagulation factors. 
Identification of the VKORC1 gene (66) led to investigations of the effect of VKORC1 
genetic variation on warfarin dosing. Several studies identified a single nucleotide 
polymorphism (c.-1639 G>A, *2) located within the promoter region of the gene that was 
associated with dose response to warfarin as measured by INR (67-70). Carriers of this 
polymorphism were more sensitive to warfarin and required a lower dosage to achieve the 
target INR (67-70), independent of the CYP2C9 genetic variation. The molecular 
mechanism behind this warfarin sensitivity is believed to be at the transcriptional level, as 
demonstrated in vitro with the -1639A allele having reduced VKORC1 promoter activity 
(68, 69). 
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Figure 1-5. Vitamin K cycle, and the involvement of warfarin, Vitamin K epoxide 
reductase, CYP2C9, and CYP4F2. 
Warfarin effectively lowers the supply of biologically active coagulation factors by 
inhibiting the conversion of Vitamin K epoxide (oxidized form) to Vitmain K 
dihydroquinone (reduced form). Vitamin K dihydroquinone is a cofactor required for the 
post-translation carboxylation of amino-terminus residues on key coagulation factors (II, 
VII, IX, X); a process that is essential for rendering these proteins biologically active. 
Vitamin K epoxide (oxidized form) is product of this carboxylation reaction, and Vitamin 
K epoxide reductase is responsible for converting the oxidized product back into Vitamin 
K dihydroquinone. CYP4F2 is a vitamin K1 oxidase, and is believed to be involvement in 
the removal of Vitamin K1 quinone from the Vitamin K cycle. Abbreviations: CYP, 
cytochrome P450 enzyme. 
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Studies using multiple regression analysis to examine the combined effect of 
CYP2C9 and VKORC1 polymorphisms, as well as clinical variables (age, sex, body surface 
area, interacting medications), found that the proportion of inter-individual variability in 
warfarin dosage accounted for by genetic factors was greater than that explained by clinical 
variables (36, 71). In a study designed to develop a warfarin-dosing algorithm, authors 
were able to explain 53-54% of the variability in warfarin doses using genetic factors along 
with clinical variables (age, body surface area, interacting medications, and indication for 
warfarin use), while clinical variables alone explained only 17-22% of dose variability 
(72). This observation was replicated in a later study where CYP2C9*2 and *3 
polymorphisms explained a combined 12% of the variation in warfarin dose, while the 
VKORC1*2 polymorphism explained 30%, and an additional 15% was explained by 
clinical variables (71). 
Unbiased detection of statistical associations between specific regions in the 
genome and a clinical outcome of interest can be accomplished using genome-wide 
association (GWA) studies. In two GWA studies that screened up to 550,000 SNPs 
spanning the whole genome in sample sizes of 300 and 1000 Caucasians, it was found that 
the statistical signals emanated from the VKORC1 gene, followed by CYP2C9 gene (73, 
74). 
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1.5.1.2 Randomized control trial evidence for genomic-guided warfarin 
therapy 
The large amount of evidence on the impact of genetic factors on warfarin dosing has given 
rise to a number of pharmacogenomic-guided dosing algorithms that incorporate CYP2C9 
and VKORC1 genotypes along with clinical variables for predicting warfarin initiation and 
maintenance doses (72, 75, 76). However, determining the net clinical benefit of the 
implementation of such algorithms into clinical practice has been challenging with RCT 
bearing positive and neutral results for genomics-guided dosing. 
The Clarification of Optimal Anticoagulation through Genetics (COAG) trial and 
two European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trials were 
published in 2013. These trials measured the benefit of genetic-guided warfarin dosing in 
patients with AF or venous thromboembolism using time in therapeutic range (TTR) as the 
primary outcome (77-79). TTR is a useful proxy measure for clinical risk of bleeding (over-
anticoagulation) or thrombosis (under-anticoagulation) as these studies were not 
sufficiently powered to detect differences in these outcomes directly. Two of the trials 
compared genomics-guided dosing with a clinical variables algorithm and found no 
statistical difference in the percentage TTR at the end of their respective follow up periods 
of four or twelve weeks (77, 78). The third trial compared a genomics-guided algorithm to 
standard dosing (no algorithm), which is more representative of usual care, and found 
significant benefits to using the genomics-guided algorithm (79). The authors reported a 
greater TTR, fewer incidences of elevated INR, and shorter times to therapeutic range when 
using their pharmacogenetic algorithm (79). 
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In 2017, the Genetic Informatics Trial (GIFT) compared genotype-guided dosing 
versus a clinical algorithm in initiating warfarin therapy for prevention of venous 
thromboembolisms (VTE) in older subjects (≥65 years) following knee or hip surgery (80). 
The primary outcome was a composite of INR ≥4, major bleeding, VTE, or death. 
Genomics-guided dosing resulted in a statistically significant reduction of the composite 
primary outcome. Notably, the authors of this study included an additional variant, 
CYP4F2*2, in their genotyping testing. 
The conflicting results from these RCTs have instigated criticism regarding the 
design and execution of these studies as well as debate surrounding the value of genomics-
guided warfarin dosing (81). For instance, the 2013 EU-PACT trial had positive findings 
using standard dosing (with dose tailored only to age) as their control arm rather than a 
clinical algorithm, essentially testing a hypothesis that differs from the other trials. In 
addition, it is well known that there are ethnic differences in the prevalence of CYP2C9 
and VKORC1 variant genotypes (82, 83), underscoring the importance of tailoring the 
variants included within a pharmacogenomics-guided dosing algorithm to account for 
prevalence of those alleles within the tested ethnic population. In the negative COAG trial, 
nearly 30% of participants were of African descent, yet the variants tested did not include 
VKORC1 and CYP2C9 variants that are more prevalent and predictive of warfarin dosing 
among African populations. Some authors believe this may have negatively impacted the 
genomic-guided arm by overdosing some African patients (81). Lastly, both the positive 
EU-PACT trial and the GIFT trial performed preemptive genotyping, where the variant 
status was known prior to initiating warfarin. Conversely, in the COAG trial only 45% of 
patients within the genomics-guided group had their variant status available for 
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incorporating into the dosing algorithm prior to receiving their first dose. Some authors 
argue that the greatest benefit for genomics-guided dosing is achieved during the initiation 
phase of warfarin dosing (81). Overall, it appears that the greatest clinical benefit is 
achieved when using genomic-guided algorithms for the initial warfarin dose selection in 
patients preemptively genotyped for variants tailored to their ancestry (84). 
 
1.5.2 Next generation of oral anticoagulants  
Not surprisingly, given the issues surrounding warfarin, direct-acting oral anticoagulants 
(DOAC) were developed and are now approved as an alternative therapy for stroke 
prevention in patients with AF, as well as prevention of venous thromboembolisms. Since 
their approval, the use of these drug in AF patients has rapidly increased (85, 86), owing 
to their ease of prescribing and management. While warfarin prescribing was complicated 
by routine INR testing and a high interpatient variability in the therapeutic dosage, DOACs 
offer fixed dosing (up to 2-fold) without the need for routine monitoring. Although DOACs 
appear to be safer than warfarin, major bleeding is still a complication associated with 
DOAC use. Furthermore, the patient population that take DOACs in the post-market setting 
may vary greatly with their co-morbidities and extensive co-medications from the often 
idealistic settings that exists within clinical trials. As prescribing trends in clinical practice 
continue to favour the use of DOACs, the number of bleeding events associated with them 
is likely to increase as well. Identifying factors that increase the DOAC-associated bleeding 
risk in patients before prescribing these drugs can help to mitigate adverse drug events. 
Factors that increase DOAC bleeding risk can be categorized into the following: advanced 
age (≥75 years), co-medication with pharmacodynamic interactions, medical conditions or 
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procedures with pre-existing bleeding risks, as well as factors that increase DOAC plasma 
concentrations. 
Although there are a number of DOACs currently available on the market, 
the remainder of this thesis will be focused on the factor Xa inhibitors, rivaroxaban 
and apixaban, as the patient population we investigated were primarily prescribed 
these DOACs. 
 
1.5.3 Factor Xa Inhibitors 
1.5.3.1 Significance of factor Xa inhibitor drug exposure 
The factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, have a pharmacological effect 
that is closely correlated to their blood concentration (87-90). Taken orally, FXaIs are 
absorbed at the level of the intestine, then enter the systemic blood circulation (at 50-100% 
bioavailability see Table 1-3) where they act on their circulating target, which is the 
activated coagulation protein factor Xa (FXa). Through reversibly binding to the active site 
of FXa with high affinity, these drugs effectively inhibit the catalytic activity of both free 
and prothrombinase-bound FXa (91, 92). From a pharmacological standpoint, this ability 
of rivaroxaban and apixaban to directly inhibit factor Xa, allows them to have a rapid onset 
and offset of action that is measured in hours (87, 89), unlike warfarin, which takes days 
to produce therapeutic efficacy (57). Inhibition of factor Xa reduces thrombin generation 
and consequently hinders clot formation given thrombin’s effects on fibrin formation and 
platelet activation. In vitro studies investigating factor Xa activity at varying concentrations 
of FXaI in human blood plasma have shown a positive relationship between increasing 
rivaroxaban and apixaban concentration and factor Xa inhibition (89, 93). Animal models 
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used to study FXaI antithrombotic efficacy have shown that a reduction in thrombus 
formation correlates with increased FXaI dose (92, 93). Hemostatic testing of FXaI-treated 
patient plasma samples to measure the sample’s ability to clot under standard conditions 
also show a concentration-dependent relationship, with longer clotting times as drug 
concentrations increase in plasma (89, 93).  
The potential relationship between the circulating concentration of FXaI and harm 
such as major bleeding in contrast to its efficacy in stroke prevention in AF or VTE in total 
knee/hip replacement was noted in the Food and Drug Administration (FDA)’s clinical 
pharmacology and biopharmaceutics reviews documents, which reported that elevated 
rivaroxaban and apixaban exposure were associated with increased risk of bleeding (94, 
95). Similarly, the more recently approved FXaI, edoxaban, was also found to have this 
positive relationship between bleeding events and plasma concentration (96). 
Consequently, patient factors that increase FXaI plasma concentration is among the listed 
factors to influence risk of hemorrhage (48, 49). 
 
  
 
 
 
24 
Table 1-3. Summary of the pharmacokinetic parameters for rivaroxaban and 
apixaban in healthy subjects. 
 
Parameter Rivaroxaban Apixaban 
Mechanism of action Factor Xa inhibitor Factor Xa inhibitor 
Bioavailability, % >80* (97) 50 (98) 
Tmax, hours 2-4 (48) 1.5-3.3 (88) 
T1/2, hours 11-13 (48) 12 (49) 
Protein binding, % 92-95 (48) 87-93 (99) 
Total Clearance, L/h † 10 (48) 3.3 (49) 
Renal clearance, % (of total 
clearance) † 
30-40 (48) 27 (98) 
Vss , L 50 (48) 21(98) 
Food effect Increase AUC by 39% 
(97) 
None (88) 
Renal excretion, % ‡ 36 (100) 22 (101, 102) 
Fecal excretion, % ‡ 7 (100) 34 (101, 102) 
CYP-mediated metabolism CYP3A4/5, CYP2J2 
(103) 
CYP3A4/5 (104) 
Drug transporters P-gp,  BCRP (105) P-gp, BCRP (106) 
Abbreviation: AUC, area-under-the-curve; BCRP, breast cancer resistance protein; Cmax, maximum 
concentration; FXa Ki, inhibition constant of Factor Xa enzyme; T1/2 , terminal elimination half-life; Tmax, 
time at maximum concentration; P-gp, P-glycoprotein; Vss , volume of distribution at steady-state. (†) After 
intravenous administration; (‡) Percent recovery of unchanged radio-labelled drug; (*) Bioavailability is 
80-100% when taken with food, or 66% without food.  
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1.5.3.2 Determinants of FXaI exposure 
Phase I pharmacokinetic studies have explored the impact of renal function, advanced age, 
and extremes of weight on rivaroxaban and apixaban exposure, often measured as the area 
underneath the plasma concentration time profile or area-underneath-the-curve (AUC). 
Kidney function is a strong determinant of FXaI drug exposure as both drugs undergo 
urinary excretion as part of their elimination process. Individuals with impaired renal 
function exhibit reduced total clearance and increased drug exposure, such that subjects 
with mild, moderate, and severe renal impairment were associated with ~16%, ~29%, and 
~44% higher AUC values for apixaban and ~44%, ~52%, and ~64% for rivaroxaban, 
respectively (107, 108). Advanced age has been shown to influence FXaI total clearance 
resulting in modest increases in drug exposure in subjects ≥65 years for apixaban (32% 
higher AUC compared to those aged 18-40 years) (109) and subjects >75 years for 
rivaroxaban (41% higher AUC compared to those aged 18-45 years) (110). However, 
differences in renal function between these age groups is likely to contribute to these 
effects. Body weight greater than or equal to 120 kg has been shown to lower the apixaban 
AUC by 23%, while body weights less than or equal to 50 kg have a 20% increase in 
apixaban AUC (111). In comparison, extremes of weight appear to have minimal effect on 
rivaroxaban exposure (112). 
Modulation of the metabolizing enzymes or transporters that are responsible for 
apixaban and rivaroxaban disposition can alter the drug concentrations achieved in the 
blood. FXaI drug metabolism is mediated primarily through the oxidative cytochrome 
P450 enzymes CYP3A4/5 and CYP2J2, although the latter applies only to rivaroxaban 
(103, 104). In vitro studies suggest rivaroxaban and apixaban are substrates to the efflux 
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transporters, P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, 
ABCG2), which are expressed highly in the intestine where these transporters influence 
FXaI absorption and in the kidneys where they influence renal excretion (105, 106). 
Concomitant medications that interact with these proteins or functional genetic variants 
that exist within their respective genes might be associated with increased systemic FXaI 
exposure and contribute to inter-individual variation in drug concentration. In particular, 
concomitant use of potent inhibitors and inducers of CYP3A4 such as ketoconazole and 
rifampin, respectively, have been shown to alter apixaban and rivaroxaban exposure by up 
to 50% change in the AUC by increasing and decreasing FXaI concentrations, respectively 
(48, 98, 113, 114). Recent work from Ueshima et al. in a Japanese AF population 
demonstrated that the ABCG2 421A/A genotype was associated with higher apixaban 
plasma concentrations at trough and reduced clearance, whilst the CYP3A5*1/*1 genotype 
was associated with lower concentrations at trough and higher clearance (115, 116). Refer 
to Figure 1.5 for the proposed disposition of apixaban and rivaroxaban, as well as Table 
1-3 for a summary of their pharmacokinetic parameters. 
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Figure 1-6. Proposed disposition of rivaroxaban and apixaban. 
Data represents percent of orally administered radio-labelled dose that is excreted in urine versus feces, taken from mass-balance 
studies carried in healthy human subjects (100, 101). Abbreviations: BCRP, breast cancer resistance protein; CYP, cytochrome P450 
enzyme; GI, gastrointestinal tract; P-gp, P-glycoprotein 
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1.6  Human genetic variation and pharmacogenetics 
Sequencing the human genome (117-119) accelerated investigations of the influence of 
genetic variation on human health and disease. Within the roughly 3.1 billion base pairs of 
the average human genome, over 12 million common sequence variations (excluding 
structural variants) (120) have been identified across world populations. These variations 
can be classified according to their prevalence within a specific population as well as by 
their nucleotide composition. The latter can be further categorized into structural or single 
nucleotide variants ( 
Figure 1-7). 
 
1.6.1 Single nucleotide variants 
Single nucleotide variants (SNVs) are sequence variations that occur throughout the 
genome, in which a single deoxyribonucleic acid (DNA) base pair is substituted for 
another. They are the most abundant form of genetic variation and based on the frequency 
of the minor allele in a human population, are referred to as either common or rare SNVs. 
Common SNVs, also called single nucleotide polymorphisms (SNPs), have a minor allele 
frequency (MAF) of at least 1%, with most having a frequency greater than 5%. The vast 
majority of SNVs that are present in an individual are common (121). Rare or novel de 
novo SNVs have a MAF less than 1%, and are sometimes referred to as a mutation, 
especially when they have a confirmed deleterious effect. 
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Figure 1-7. Types of genetic variation. 
Genetic variation can be classified based on the number of nucleotides that are implicated, 
which can range from as small as a single nucleotide variant all the way up to a complete 
loss or gain of a chromosome (aneuploidy).  
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Aside from allele frequency, SNVs can differ in their location with respect to a 
gene, and their translated effect at the protein level (Figure 1-8). Within the coding region, 
areas of the genome that undergo transcription and translation, nucleotide substitutions 
have the potential to alter the amino acid sequence of a polypeptide. A synonymous SNV 
is defined as a nucleotide substitution that creates a codon that codes for the same amino 
acid. Nonsynonymous SNVs occur when a nucleotide substitution creates a codon that 
either codes for a different amino acid or a premature stop codon. These variants have 
potential implications on the structure and/or function of a protein. In addition, SNVs can 
reside within noncoding regions. SNVs that occur within intron-exon boundaries can 
interrupt the splicing pattern required to form the appropriate messenger ribonucleic acid 
(mRNA) transcript required for a functional protein. Furthermore, SNVs can occur within 
regulatory elements (which include promoters, enhancers, repressors) and potentially alter 
the expression of a gene. 
 
 
 
 
Figure 1-8. Type of single nucleotide variation. 
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1.6.2 Evolution of pharmacogenetics 
In pharmacology, an individual’s response to a drug can be considered a phenotype, 
whether the individual is experiencing toxicity or the desired pharmacological effect. 
Pharmacogenetics is the study of the influence of genetic variation on drug response, 
typically by way of altering pharmacokinetics (absorption, distribution, metabolism, or 
elimination) or pharmacodynamics (target of a drug, or drug sensitivity). Prior to recent 
advancements, the discoveries that shaped the field of pharmacogenetics came from 
studying families for patterns of inheritance for specific drug responses, eventually leading 
to molecular studies that revealed the genetic determinant for that response phenotype 
(122). Pharmacogenetic research was greatly advanced by the elucidation of the human 
genome sequence and identification of the common genetic variations within the human 
population, together with developments in sequencing and genotyping technologies. While 
previous strategies relied on the candidate-gene approach (pre-selection of genes based on 
a priori knowledge), SNP genotyping arrays have enabled unbiased genome-wide analyses 
associating SNPs to drug phenotypes through GWA studies. There have been a number of 
important genotype-phenotype associations identified in pharmacogenetics using GWA 
studies (123-126). A prominent example of this is the association of common SNVs within 
the genes, CYP2C9 and VKORC1, with variability in warfarin drug response (73, 74). To 
date, these arrays have been used to identify several common polymorphisms as genetic 
factors that influence variability in drug response. Unfortunately, the commonly used 
genotyping platforms limit the identification of rare or novel SNVs, thus the investigation 
of rare variations requires more comprehensive sequencing technologies. 
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1.7 DNA sequencing technologies 
DNA sequencing technologies have improved greatly over the past twenty years, reducing 
the cost and time requirements of large scale sequencing projects. Interestingly, the initial 
sequencing of the human genome (117) was carried out using a method developed in 1977 
(127) by Sanger and his colleagues now known as “Sanger” sequencing. This method was 
part of a first generation of sequencing technologies, has now been succeeded by a second 
generation of sequencing technologies. These next generation sequencing (NGS) platforms 
that drastically improved sequencing cost and time through massive parallelization of 
sequencing reactions achieved by miniaturizing sequencing reactions and improving 
detection systems. 
 
1.7.1 Sanger sequencing 
In this approach, a single stranded DNA template is replicated several times over using 
DNA polymerase, an oligonucleotide primer, deoxyribonucleotide-triphosphates (dNTPs), 
and fluorescently labelled dideoxyribonucleotide-triphosphates (ddNTPs). During DNA 
synthesis, the incorporation of ddNTPs terminates the elongation of the complementary 
strand as ddNTPs lack the required 3ʹOH for elongation. The presence of both ddNTP and 
dNTP enables the synthesis of complementary DNA strands of varying lengths with one 
of four fluorescently labelled ddNTPs (ddATP, ddTTP, ddGTP, ddCTP) on their 3ʹ ends. 
After several rounds of template DNA extension, the resulting reaction product is injected 
onto a capillary and separated according to size with the smallest fragments undergoing 
excitation and detection of fluorescence signal first. This produces four electropherograms 
that are superimposed to produce the final sequence. The major drawbacks of this method 
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are the price per base and its inefficiency for large scale sequencing projects. Sanger 
sequencing of the human genome in the Human Genome Project was a 13-year, $2.7 billion 
effort. 
 
1.7.2 Illumina sequencing 
Today, the Illumina sequencer is one of the most commonly used next generation 
sequencing (NGS) platforms. The methodology involves bridge amplification to produce 
clusters of clonally enriched template DNA that are then sequenced in a sequencing-by-
synthesis manner. 
 
1.7.2.1 Cluster generation 
First, template DNA is fragmented and two different sets of adapters are attached to the 
termini of each fragment. The adapters serve as an annealing site for sequencing primers, 
as well as a method of attachment to the flow cell (sequencing apparatus). Next, fragments 
are denatured to form single stranded template DNA that is injected into the flow cell. The 
flow cell is a glass surface densely coated with different oligonucleotides that are 
complementary in sequence to the adapters at each end of the template DNA, so that upon 
injection, the fragments become attached to the surface of the flow cell. Then, a polymerase 
creates a complement of the hybridized fragment and the original template DNA is washed 
away. The remaining fragments are then amplified through bridge amplification, 
transforming single fragments into clonal clusters. 
Bridge amplification begins with an annealing step, where the free adapter end tips 
over and hybridizes to a complementary oligonucleotide on the flow cell forming a bridge. 
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Next, polymerase chain reaction (PCR) reagents are added to synthesize the 
complementary strand. Then, the two strands are denatured, which disassociates the bridge. 
This process of bridge amplification is cycled repeatedly until each cluster contains 
approximately 1000 clonally amplified fragments, at which point they are ready for 
sequencing. 
 
1.7.2.2 Sequencing-by-synthesis 
The first cycle of sequencing begins with the introduction of DNA polymerase, a primer, 
and four fluorescently-labelled nucleotides into the flow cell. After primer annealing, a 
single complementary dNTP is incorporated, and the excess dNTPs are washed away. The 
fluorescent label also serves to terminate further extension of the sequence, so that only 
one nucleotide is added at a time. The fluorescent dyes are then excited and an image is 
taken, capturing an emitted signal for each cluster in the flow cell. The chemical groups 
containing the fluorescent dye are enzymatically removed recovering the 3ʹOH group, to 
allow for the next cycle of dNTPs to be added and imaged. These series of images are then 
assembled and analyzed by computer software to put together the sequence for the tens of 
millions of clusters. 
 
1.7.3 Targeted exome sequencing 
Although NGS enables the unbiased detection of common, rare, or novel variations, whole 
genome sequencing is still a costly endeavour. This cost encompasses the price for 
sequencing as well as data storage and processing. Exome sequencing is a more focused 
method of sequencing that is limited to the protein coding regions, which comprise 
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approximately 1% of the human genome (128). These “targeted” exome capture strategies 
enable deep sequencing of a relatively small number of selected genes of interest 
(cumulatively less than 1,000,000 bp), decreasing error rates and uncertainly in genotype 
calling that are frequently associated with short-read NGS data (129). Fundamentally, 
targeted exome NGS (Figure 1-9) requires the capture and enrichment of genomic regions 
of interest before sequencing. The target-enrichment strategies that can be used include 
PCR-based, molecular inversion probe (MIP)-based, or hybrid oligonucleotide capture-
based approaches, all of which can vary in their performance relative to one another (130). 
The possibility of using NGS to sequence genes pertinent to drug disposition and drug 
response is of particular relevance in the fields of pharmacogenetic research and clinical 
genotyping to implement personalized genotype-based therapies 
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Figure 1-9. Targeted next generation sequencing workflow.
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1.8 Summary 
Factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, represent a new class of oral 
anticoagulants that are a safe and efficacious alternative to warfarin therapy for stroke 
prevention in patients with AF. Given their mechanism of action, FXaI pharmacological 
effect can be inferred based on the observed plasma drug concentration. Consequently, 
prolonged periods of elevated FXaI concentration are associated with increased risk for 
major bleeding. Currently, there is a paucity of data relating to observed interpatient 
variation in FXaI plasma concentrations in the post-market clinical setting. The patient 
population that take FXaIs in the post-market setting may vary greatly with their co-
morbidities and extensive co-medications from those within clinical trials. Therefore, the 
systemic FXaI exposures achieved in these individuals may vary greater than those 
observed in clinical trials, and this interpatient variation is likely driven by patient-specific 
factors that comprise an individual’s physiology, disease-state, environment (e.g. co-
medications, food), as well as genetics. Renal impairment, age, sex, extremes in weight, as 
well as common single nucleotide variants (SNVs) in metabolizing enzymes and 
transporters that are responsible for apixaban and rivaroxaban disposition have been 
indicated to alter the elimination of FXaIs from the body, and are predictive of systemic 
apixaban exposure. Similarly, endogenous biomarkers of FXaI metabolism may serve as 
an additional predictor of drug exposure. While previous research surrounding the 
influence of genetics on drug exposure has been focused on evaluating common functional 
variation, more recent evidence suggest rare SNVs in drug processing genes may also 
significantly contribute to interpatient differences in drug disposition beyond established 
common genetic predictors (131-133). Thus it is intriguing to speculate that AF patients 
38 
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who demonstrate unexpectedly high or low FXaI plasma concentration may harbor rare or 
patient-specific SNVs that result in aberrant function or expression of their FXaI 
metabolizing enzyme or transporter, consequently impacting their drug exposure. 
  
39 
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2 Specific Aims and Hypotheses 
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2.1 Specific aim 1 
1. To measure the extent of the variability in plasma apixaban and rivaroxaban 
concentration within atrial fibrillation (AF) patients in a routine care setting. 
 
Factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, represent a new class of oral 
anticoagulants that are widely prescribed as an alternative to warfarin therapy for stroke 
prevention in patients with AF. An important advantage of these drugs is that routine 
monitoring of anticoagulation response is not necessary. Nevertheless, because of their 
mechanism of action a FXaI anticoagulation effect can be inferred based on the observed 
plasma concentration, with prolonged periods of elevated FXaI concentration associated 
with increased risk for major bleeding. Currently, there is a paucity of data relating to 
observed interpatient variation in FXaI plasma concentrations in the post-market clinical 
setting. Given that the patient population that take FXaIs in the post-market setting may 
vary greatly with their co-morbidities and extensive co-medications from those within 
clinical trials, the systemic FXaI exposures achieved in these individuals may vary greatly 
as well. 
 
We hypothesize that the variation in the apixaban and rivaroxaban concentration 
within the routine care setting is greater than the variation observed during clinical 
trials.  
 
To test this hypothesis, we determined rivaroxaban and apixaban plasma concentrations in 
a cohort of 243 AF patients during routine clinic visits. As described in Chapter 4, in our 
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routine-care setting rivaroxaban and apixaban plasma concentrations tended to be more 
variable than those observed in clinical trials.  Approximately 12% of patients receiving 
rivaroxaban and 13% of patients receiving apixaban exceeded the 95th percentile for the 
predicted maximum FXaI plasma concentration (Cmax) observed in clinical trials. Overall, 
identification of additional clinical and molecular determinants that more fully predict 
patients at risk for excessively high or low FXaI concentrations may enable a more precise 
FXaI dosing regimen for the individual patient.  
 
2.2 Specific aim 2 
1. To identify predictors of variability in FXaI plasma concentration among 
apixaban-treated AF patients using clinical variables, common genetic variation, 
and an endogenous biomarker for apixaban metabolism.  
 
Apixaban undergoes multiple pathways of elimination that include both metabolism, and 
excretion, though renal, intestinal, and biliary mechanisms (1, 2). Factors that influence 
these elimination pathways such as renal function, age, sex, weight, and common genetic 
polymorphisms have been demonstrated to alter the pharmacokinetics of apixaban in 
subjects, and are predictive of systemic apixaban exposure (3-6). Similarly, identifying a 
factor that can be used as a measure of apixaban metabolism (endogenous biomarker) may 
serve as an additional predictor of variability in apixaban exposure, especially given that 
roughly one third of orally administered apixaban is excreted from the body in metabolite 
form. Hepatic and intestinal cytochrome P450 3A enzymes (CYP3A4/5) are responsible 
for the phase I metabolism (oxidation) of apixaban (7, 8). In humans, 4β-
hydroxycholesterol (4β-OHC) is an endogenous oxysterol, present in the blood, that is 
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created through the conversion of cholesterol by CYP3A enzymes (9), and is recognized 
as an emerging biomarker of CYP3A activity. Therefore, by examining 4β-OHC as a 
marker for apixaban metabolism, together with factors that are known to impact apixaban 
exposure (renal function, age, sex, weight, and common genetic variation), we are likely 
able to better explain the variation in concentration observed within our apixaban-treated 
cohort. 
 
We hypothesize that CYP3A activity, as measured by 4β-OHC concentration is a 
predictor of apixaban plasma concentration, and together with known clinical and 
genetic determinants of apixaban exposure will better explain interpatient variation 
in FXaI concentration compared to clinical and genetic factors alone. 
 
To test this hypothesis, we determined 4β-OHC plasma concentrations in 136 characterized 
and genotyped AF patients. As described in Chapter Four, we found a weak but statistically 
significant correlation between plasma concentrations of apixaban and 4β-OHC, with 
higher 4β-OHC concentrations (higher CYP3A4 activity) associated with lower apixaban 
concentrations. Regression analysis demonstrated that 4β-OHC concentration was an 
independent predictor of apixaban concentration in our cohort, along with age, female, 
serum creatinine, and amiodarone use. Weight, diltiazem use, as well as CYP3A4*22, 
CYP3A5*3, ABCB1 c.3435C>T, or ABCG2 c.421C>A carrier status were not significant 
predictors of apixaban plasma concentration in our cohort.  
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2.3 Specific aim 3 
1. To develop a targeted next generation sequencing (NGS) approach for the 
detection of genetic variation in pharmacogenes pertinent to drug disposition and 
response. 
2. To apply this method for single nucleotide variant (SNV) discovery in a small 
cohort of apixaban-treated AF patients with aberrantly high drug plasma 
concentrations.  
 
In Chapter Four, we noted that known common genetic variation in metabolizing enzymes 
and efflux transporters (CYP3A4*22, CYP3A5*3, ABCB1 c.3435C>T, or ABCG2 
c.421C>A) were not significant predictors of interpatient variation in apixaban 
concentration within our AF cohort. Furthermore, a large proportion (~72%) of this 
interpatient variation remained unaccounted for within our regression analysis. Therefore, 
we proposed that rare or patient-specific single nucleotide variations (SNV) within certain 
individuals are likely contributing to this unexplained variation. While previous 
pharmacogenetic research has focused on evaluating common functional variation (minor 
allele frequency, [MAF] >5%), more recent large-scale whole genome or exome 
sequencing studies have revealed that humans harbor a large number of rare (MAF <1%), 
potentially deleterious variants in many of these pharmacogenes (10, 11). Further studies 
support that rare SNVs in drug processing or drug target genes significantly contribute to 
interpatient differences in drug disposition and response beyond established common 
genetic predictors as shown for CYP2C9 and warfarin dose requirement (12, 13) and 
SLCO1B1 and methotrexate clearance and toxicity (14). Targeted next-generation 
55 
 
 
 
55 
sequencing (NGS) represents a new time- and cost-effective technology for detecting 
common and rare genetic variation, allowing for DNA enrichment of entire exomes or 
coding exons of select genes coupled with massive parallel sequencing of the enriched 
product. Through the application of this method, particularly, in those apixaban-treated AF 
subjects who demonstrated unexpectedly high drug plasma concentrations, we would be 
able to better identify those individuals with rare or patient-specific SNVs that result in 
aberrant function or expression of their CYP enzyme or transporter, consequently 
impacting their apixaban exposure. 
 
We hypothesize apixaban-treated AF subjects with aberrantly high apixaban plasma 
concentrations harbor rare or patient-specific functional SNVs within genes involved 
in the metabolism and transport of apixaban.  
 
To test this hypothesis, we generated a custom panel of capture probes to enrich a target 
sequence of 422 kb of coding region in 100 pharmacogenes, including seven genes that are 
relevant to apixaban disposition. NGS was carried out in 245 subjects (n=48/245 validation 
cohort; n = 12/245 apixaban-treated AF cohort). As described in Chapter five we generated 
a sufficient depth-of-coverage (DOC) > 30 × for 97.4% of the target sequence, with a total 
of 1089 variants detected in 245 subjects. Selected SNVs (32 common and 5 rare or novel) 
identified through NGS were found to be concordant with TaqMan genotyping and Sanger 
sequencing results. Importantly, 60% of total variants were rare or previously unreported, 
with a greater proportion of rare or novel SNVs predicted to alter protein function 
compared to common SNVs. Each subject carried at least one predicted functional variant 
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on both alleles across our target sequence, and 161 subjects (66%) were homozygous 
carriers for at least one clinically actionable variant. More specifically, of the apixaban-
treated AF subjects that were sequenced, our exploratory analysis did not reveal potentially 
deleterious SNV(s) within the selected candidate genes that may further explain their 
observed elevated apixaban plasma concentration. 
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3 Interpatient Variation in Rivaroxaban and 
Apixaban Plasma Concentrations in Routine 
Care (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Reprinted with permission from Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes 
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3.1 Introduction  
Direct-acting oral anticoagulants (DOACs) that target key rate-limiting enzymes in the 
coagulation cascade are rapidly replacing warfarin as therapeutic agents of choice for 
stroke prevention in the setting of atrial fibrillation (AF), as well as prevention or treatment 
of venous thromboembolism (1-8). A key perceived advantage associated with the use of 
DOACs is the relative ease in dosing and no requirement for routine monitoring of 
anticoagulation response, such as INR (9).  
Rivaroxaban and apixaban, both Factor Xa (FXa) inhibitors, elicit their 
pharmacological effect in a concentration-dependent manner (10-14). Preclinical studies 
measuring isolated human FXa enzyme activity over varying drug concentrations 
demonstrated an inhibitory effect proportional to spiked plasma drug concentrations (2, 
15).  During Phase I (in-human) studies, these findings translated into prolonged clotting 
times, with the anticoagulation effect directly relating to plasma concentration (10-14).  As 
such, there is a particular concern for increased bleeding risk with higher plasma 
concentrations which has spurred the development of reversing agent for use in the setting 
of major bleeding events (16-18). 
The European Medicines Agency (EMA) and US Federal Drug Administration (FDA), 
have shown interest in defining an acceptable therapeutic index that is clinically impactful 
and actionable (16, 18, 19). To address the gap in knowledge of DOAC drug concentrations 
in patients during routine care, we aimed to assess DOAC concentrations in patients with 
existing AF who were prescribed rivaroxaban or apixaban as a part of standard care.  
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3.2 Materials and Methods  
3.2.1 Study design and participants  
This prospective cohort study was carried out at the London Health Sciences Center, 
University Hospital in London, Ontario. Patients with existing atrial fibrillation (AF) 
prescribed rivaroxaban or apixaban at Cardiology or Anticoagulation Clinics were invited 
to participate. Inclusion and exclusion criteria are outlined in Figure 3-1. The study 
protocol was approved by the Health Sciences Research Ethics Board of the University of 
Western Ontario (London, Canada), and written informed consent was obtained. The study 
was conducted over a 3-year period (February 2013 and January 2016).  
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Figure 3-1. Patient flow diagram.  
Enrolled patients must have been on the same dose for ≥ 4 days at the recommended dosing 
cycle for rivaroxaban (once daily) and apixaban (twice daily), with only those samples 
collected >2 (rivaroxaban) and >3 (apixaban) hours post dose to be considered in the drug 
concentration analysis. Abbreviations: LHSC, London Health Sciences Center; Tmax = 
time of maximum concentration.  
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3.2.2 Clinical data collection  
Patient age, sex, weight, and height was collected at the time of blood sampling, along with 
their most recent serum creatinine concentration to the time of draw. Renal function is 
known to have a greater effect on observed rivaroxaban plasma concentration when 
compared to apixaban (20). Renal function was monitored by determining the estimated 
creatinine clearance (eCrCl) using the Cockcroft-Gault formula. Rivaroxaban and apixaban 
are both reported substrates of the drug efflux transporter P-glycoprotein (P-gp), and drug 
metabolizing cytochrome P450 (CYP) enzyme CYP3A4 (21-24). Accordingly, 
concomitant use of moderate (amiodarone, diltiazem, fluconazole, verapamil) to strong 
(clarithromycin, ketoconazole, ritonavir) P-gp/CYP3A4 inhibitors(25), and P-gp/CYP3A4 
inducers(25) (carbamazepine, phenytoin, phenobarbital rifampin) were documented at the 
time of sampling.  
 
3.2.3 Sample collection, processing, and storage  
Blood samples were obtained from each patient while taking their prescribed dose of 
rivaroxaban or apixaban. Date and time of last dose and blood collection was recorded and 
time since last dose (hours) was subsequently calculated. Blood samples were immediately 
placed at 4°C, prior to centrifugation at 2000 g for 10 minutes for plasma isolation.  Plasma 
samples were stored at -80°C until further analysis.  
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3.2.4 Determination of rivaroxaban and apixaban plasma 
concentration. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays for rivaroxaban 
and apixaban were developed and validated using modified protocols (26, 27). 
Rivaroxaban, rivaroxaban-D4, and apixaban were obtained from Toronto Research 
Chemicals (Toronto, Canada) and dissolved in dimethyl sulfoxide at 1mg/ml.  [13C, 2H7]-
Apixaban (Alsachim, Illkirch-Graffenstaden, France) was dissolved in methanol at 
1mg/ml. Calibration standards (0, 5, 10, 25, 50, 100, 150, 250, 500, 750, 1000 ng/mL) and 
quality controls (QCs) (25, 250, 1000 ng/ml) were prepared in drug-naïve, non-filtered (K2-
EDTA) human plasma (Bioreclamation IVT, Maryland, USA).  QCs were used to calculate 
the precision and accuracy of the assay according to standards of the FDA Bioanalytical 
Method Validation for chromatography (28). Standard or QC plasma (100 µl), and patient 
plasma (50 µl) were respectively dissolved in 300 µl and 150 µl of acetonitrile spiked with 
rivaroxaban-D4 or [13C, 2H7]-apixaban as an internal standard. Samples were kept at 
ambient temperature for 5 minutes followed by centrifugation at 13,500 rpm for 20 min at 
4°C. A volume of 100 µl of the supernatant was subsequently diluted with 75 µl of 0.1% 
formic acid in H2O and transferred to glass auto-sampler vials. Chromatographic separation 
was performed using an Agilent1200 G1312 Binary Pump (Agilent Technologies, Santa 
Clara, USA) and a Hypersil GOLDTM C18 (50mm x 3mm ID, 5 µm particle size) column 
(Thermo Scientific, San Jose, USA), with an injection volume of 40 µl. Mobile phases used 
for gradient elution were 0.1% formic acid in water and acetonitrile.  The mass analysis 
was performed on a TSQ Vantage triple-quadrupole mass spectrometer (Thermo 
Scientific). The following mass transitions were monitored in positive mode for 
quantification: apixaban, 460.1⟶ 443.3 m/z; [13C, 2H7]-apixaban, 468.1⟶ 451.4 m/z; 
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rivaroxaban, 436.4⟶144.9 m/z; and rivaroxaban-D4, 440.8⟶144.9 m/z. Assay 
performance across the 25, 250, and 1000 ng/ml QCs were as follows: inter-day bias 
(accuracy)  and precision were respectively less than or equal to 5.2% and 4.2% for 
rivaroxaban, and 1.5% and 8.5% for apixaban; intra-day bias and precision were 
respectively less than or equal to 5.3% and 3.5% for rivaroxaban, and 1.3% and 5.1% for 
apixaban.  
 
3.2.5 Reference rivaroxaban and apixaban clinical trials population 
pharmacokinetics data.  
To compare the distribution of measured single time-point plasma concentrations in 
relation to clinical trials, rivaroxaban and apixaban treated AF population concentration 
data were sourced from Girgis et al (29) and the Eliquis® (apixaban) product monograph 
(30) respectively. Rivaroxaban measured concentrations were compared to the population 
concentration-time profile sourced from Girgis et al (presented in Figure 3-2, as median 
and 5th-95th percentile).  Maximum and minimum concentration values were taken directly 
from the concentration-time profile. This simulated concentration-time profile of the 20 
mg once daily rivaroxaban dose was obtained through population pharmacokinetic 
modelling of sparsely sampled plasma concentration data from phase III (ROCKET AF) 
rivaroxaban-treated atrial fibrillation patients (29). For apixaban, there are currently no 
available published pharmacokinetic data that describe the entire time course of apixaban 
concentrations specific to atrial fibrillation patients. Therefore, measured concentrations 
were compared in relation to the maximum (Cmax) and minimum (Cmin) plasma 
concentration values over the dosing interval (presented in Figure 3-3, as median and 5th-
95th percentile) provided in the Eliquis® (apixaban) product monograph for nonvalvular 
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atrial fibrillation patients prescribed apixaban 5 mg twice daily. Specifically, we assessed 
whether the measured apixaban concentrations fell within the range of 41 ng/ml to 321 
ng/ml, representing the lower limit for Cmin (5th percentile) to the upper limit for Cmax 
(95th percentile) respectively (30). 
 
3.2.6 Statistical analysis 
Analysis was performed using the statistical software, SPSS (Armonk, USA) and 
GraphPad Prism 6 (La Jolla, USA).  
 
3.3 Results  
3.3.1 Patient characteristics  
We analyzed DOAC concentration data from 243 AF patients (rivaroxaban, n=94; 
apixaban, n=149) with subject characteristics summarized in Table 3-1. Compared to 
clinical trials, our cohort had a higher proportion of females as well as higher rates of 
concomitant moderate P-gp/CYP3A4 inhibitor use (amiodarone, verapamil, diltiazem). 
For apixaban, our cohort had a higher percentage of patients who were ≥75 years of age 
when compared to patients enrolled in the ARISTOTLE and AVERROES clinical trials 
(50.3% compared to 31.2% and 33.8%, respectively). 
 
 67 
Table 3-1. Study population characteristics in relation to published trials. 
  
Current Study Published  Trials 
Characteristic 
  
ROCKET AF 
(5) 
ARISTOTLE 
(31) 
AVERROES(6) 
Drug Rivaroxaban Apixaban Rivaroxaban Apixaban Apixaban 
Subjects, n 94 149 7131 9120 2808 
Age, median (IQR) or mean (SD) 68 (60-78) 75 (66-82) 73 (65-78) 70 (63-76) 70 (9) 
Age, ≥65 years, (%) 60.6 79.2 76.9 (32) 69.9 (33) 69.3 
Age, ≥75 years, (%) 30.9 50.3 44.0 (34) 31.2 33.8 
Sex, Female (%) 45.7 47.7 39.7 35.3 41.5 
BMI, kg/m2, median (IQR) or mean 
(SD) 
29 (24-34) 29 (25-34) 28 (25-32) NR 28 (5) 
Weight, kg, median (IQR) 82 (70-99) 83 (70-97) NR 82 (70-95) NR 
CHADS2, mean (SD) 2.0 (1.3) 2.6 (1.3) 3.5 (1.0) 2.1 (1.1) 2.0 (1.1) 
Rivaroxaban Dose 
     
15 mg daily, (%) 25.5 - 20.7 (35) - - 
20 mg daily, (%) 74.5 - 79.2 (35) - - 
Apixaban Dose 
     
2.5 mg twice daily, (%) - 38.3 - 4.7 6.4 
5 mg twice daily, (%) - 61.7 - 95.3 93.6 
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Concomitant moderate P-gp and 
CYP3A4 Inhibitor use, (%) 
 
30.9 
 
30.8 
 
18.2 (36) 
 
- 
 
- 
Amiodarone, (%) 11.3 13.4 NR 11.1 11.0 
Diltiazem and Verapamil, (%) 19.6 17.4 NR NR 9.0 
Concomitant P-gp and CYP3A4 
Inducer use, (%)  
 
5.2 
 
2.8 
 
NR 
 
NR 
 
NR 
Phenobarbital, (%)      0.0 0.7 NR NR NR 
Phenytoin, (%)      3.1 0.7 NR NR NR 
Carbamazepine, (%)    2.1 0.7 NR NR NR 
Rifampicin, (%)    0.0 0.7 NR NR NR 
Hours post dose, mean (min-max) 11.8 (2-23.5) 6.2 (3-11.9) - - - 
Renal function, creatinine clearance* 
subjects, n  
 
94 
 
149 
7111 (32) 9120 (33) 2798(33) 
Normal (>80 ml/min), (%) 52.1 37.6 32.2 (32) 41.2 (33) 34.0 (33) 
Mild (50-79 ml/min), (%) 24.5 32.9 46.6 (32) 41.9 (33) 38.2 (33) 
Moderate (30-49 ml/min), (%) 17.0 21.5 21.0 (32) 15.0 (33) 17.5 (33) 
Severe (15-30 ml/min), (%) 2.1 3.3 NR 1.5 (33) 2.0 (33) 
Not Reported, (%) 4.3 4.7 0.2 (32) 0.4 (33)  8.3 (33) 
Serum Creatinine, µmol/L, median 
(IQR) 
84 (69-98) 91 (72-111) NR NR NR 
Abbreviations: BMI, body mass index; IQR, interquartile range; NR, not reported; SD, standard deviation; Data represented as: percent 
of cohort (%), median (IQR, 25th and 75th percentile), mean (±SD); *Creatinine clearance estimated using Cockcroft-Gault formula for 
patients with available serum creatinine.  
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3.3.2 Rivaroxaban plasma concentrations 
We observed approximately 60-fold variation, based on minimum to maximum plasma 
concentration across the dosing interval, in patients prescribed rivaroxaban 20 mg daily 
(n=70) and 15 mg daily (n=24). When the observed concentrations in this cohort of patients 
were plotted in relation to AF population concentration-time profiles assessed during 
clinical trials (See Methods, for Figure 3-2 reference details)(29), 40.4% (n=38) of 
rivaroxaban patient values were outside the predicted 5-95th population percentile for 
concentrations (Figure 3-2). Of the 38 patients outside the predicted concentration range, 
21 were above the 95th percentile while 17 were below the 5th percentile. Eleven (11.7%) 
of measured concentrations across the dosing interval exceeded 363.9 ng/ml, which is the 
estimated upper limit (95th percentile) of Cmax for an AF patient taking rivaroxaban 20 
mg once daily at steady-state (29). Rivaroxaban plasma concentrations were also plotted 
according to those above or below the estimated creatinine clearance threshold used for 
dose selection (50 ml/min) (Figure 3-2B). 
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Figure 3-2. Rivaroxaban plasma concentration in AF patients within routine care. 
Observed plasma rivaroxaban concentration in relation to dose (A) and criteria required for 
appropriate dosing: estimated creatinine clearance (B), superimposed on to clinical trial 
pharmacokinetic population data for atrial fibrillation (AF) patients (See Methods). 
Estimated creatinine clearance calculated using Cockcroft-Gault’s formula, patients 
missing serum creatinine data were excluded (n=4, panel B). Abbreviations: Cmax 
maximum concentration; Cmin, minimum concentration.  
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3.3.3 Apixaban plasma concentrations 
A 50-fold variation (minimum to maximum) was observed in measured plasma 
concentrations for both apixaban dosing regimens: 5 mg twice daily (n = 92) or 2.5 
mg twice daily (n = 57). Of the combined 149 patients, 24 (16.1%) attained 
concentrations outside the maximum (Cmax, 95th percentile) and minimum (Cmin, 
5th percentile) plasma concentration values reported in the Eliquis product 
monograph for AF patients taking 5 mg twice daily (Figure 3-3A). More specifically, 
19 versus 5 patients had concentrations above and below the reported Cmax and 
Cmin, respectively.  
The recommended apixaban dose for stroke prevention in AF patients is 5 mg 
twice daily, or the reduced 2.5 mg twice daily dose in those fulfilling 2 of following 
3 clinical criteria: age ≥ 80 years, serum creatinine ≥133 µmol/L, and weight ≤60 kg. 
The observed apixaban concentrations were also plotted according to these clinical 
criteria (Figure 3-3B-D).   Plasma concentrations of patients taking 5 mg versus 2.5 
mg twice daily (220.6 ng/ml compared to 173.3 ng/ml) were similar with only a 
modest 1.27-fold difference between the mean measured apixaban concentrations.    
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Figure 3-3. Apixaban plasma concentration in AF patients within routine care 
Observed plasma apixaban concentration in relation to dose (A), and criteria required for 
appropriate dosing: age (B), serum creatinine (C), and weight (D). Measured concentration 
compared to predicted maximum (Cmax) and minimum (Cmin) plasma concentrations 
values for 5 mg twice daily dose, as noted in the apixaban product monograph for atrial 
fibrillation (AF) patients. Patients missing serum creatinine data were excluded (n=7, panel 
C). 
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3.3.4 Concomitant P-glycoprotein and CYP3A4 inhibitors and 
inducers 
Currently there are no recommendations regarding concomitant use of moderate P-
gp/CYP3A4 inhibitors such as amiodarone and diltiazem. In our patients, these agents were 
prescribed in 30% of our cohort. We compared DOAC plasma concentrations of 
concomitant amiodarone and diltiazem users to non-users. There was a lack of relationship 
between moderate inhibitor use and DOAC plasma concentrations, however, this study was 
not well powered to determine the effect of moderate inhibitor use on DOAC plasma 
concentrations. We were also unable to assess the effect of P-gp/CYP3A4 inducing 
medications on DOAC concentrations as few patients were co-prescribed these 
medications. 
 
 
3.4 Discussion 
3.4.1 Study Summary 
This study examined the extent of interpatient variation in plasma DOAC concentrations 
in AF patients in a routine clinical care setting, prescribed rivaroxaban or apixaban in 
comparison to that observed in clinical trials. Plasma concentrations of both rivaroxaban 
and apixaban exhibited marked interpatient variability in that 40% of rivaroxaban patients 
were outside the 5-95th population percentile ranges for plasma concentrations observed in 
clinical trials, of which 11.7% exceeded the upper limit (95th percentile) for Cmax (29). 
Similarly for apixaban, 12.8% of our patients were above the 95th percentile for Cmax, 
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whereas 3.4% were below the 5th percentile for Cmin, as outlined in the apixaban (Eliquis) 
product monograph (30).   
 
3.4.2 Potential clinical relevance of our findings  
Currently, there are no approved blood tests for anticoagulation response to monitor DOAC 
therapy. Although the attained plasma concentration of DOACs mirror their inhibitory 
effects (whether thrombin or FXa) on their target (2, 10, 12, 15, 37, 38) the utility of a 
pharmacokinetic-based approach to improving DOAC therapy is dependent on the 
association between drug exposure and clinical response. The potential relationship 
between FXa inhibitor circulating concentration and harm (major bleeding) versus efficacy 
(stroke prevention in AF, venous thrombotic embolism (VTE) in total knee/hip 
replacement) was noted in the FDA’s Clinical Pharmacology and Biopharmaceutics 
Reviews documents (21, 39).  In addition, there is sufficient evidence to suggest the use of 
ketoconazole, a potent P-gp and CYP3A4 inhibitor, increases DOAC exposure by 
approximately 2-fold (40, 41). Due to the associated increased bleeding risk, ketoconazole 
is contraindicated in patients taking rivaroxaban or apixaban (30, 42). 
However, at the present time, the precise DOAC concentration thresholds that 
accurately predict for over- or under-anticoagulation have not been established. Additional 
studies involving therapeutic drug monitoring (TDM) may help to establish a therapeutic 
index. Ideally, such a therapeutic index will then define an optimal plasma concentration 
range that provides greatest benefit, that of stroke prevention for AF patients, while 
minimizing bleeding risk. We note for the latest DOAC to attain regulatory approval, 
edoxaban, a detailed assessment of edoxaban exposure vs bleeding and stroke or systemic 
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embolic event risk was published as part of the ENGAGE AF-TIMI 48 trial. Interestingly, 
the slope for bleeding risk was steeper, relative to the slope for stroke prevention, 
particularly when the trough concentration exceeded 100 ng/ml (43). 
 
3.4.3 Limitations 
This is an observational study of patients who were recruited during their routine care 
visits.  As such, this limits our ability to account for the effect of adherence as well as 
inaccurate self-reporting of time of last-dose on the drug concentration.  It remains possible 
that unreported missed doses or drug intake without food (rivaroxaban only) may explain 
some of the inter-patient variability especially in patients with very low plasma 
concentrations. Finally, this study lacks adequate sample size to assess clinically relevant 
outcomes, such as major bleeding, stroke, or death. Prospective studies in routine care 
patients that focus on attained DOAC concentration in relation to outcomes are needed.  
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3.4.4 Conclusion  
In this study, we demonstrate variation in DOAC plasma concentrations in routine care are 
greater than that observed in clinical trials. Therapeutic drug monitoring may be helpful in 
DOAC dosing and selection for a subset of patients with variable renal function or 
requiring concomitant medications that can alter DOAC disposition.  Overall, DOACs 
represent an important new class of medications which are widely prescribed as an 
alternative to warfarin therapy, and increasingly recommended as the initial oral 
anticoagulant in the setting of AF with risk factors for stroke (8). Additional research 
focused on the association of clinical and genetic variables to DOAC concentration and 
clinical outcomes are needed. 
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4.1 Introduction 
Factor Xa inhibitor, apixaban, belongs to an increasingly prescribed class of direct-acting 
oral anticoagulants (1, 2) used for prevention of stroke (3-5), and venous 
thromboembolisms (VTE) (6, 7). Under the setting of stroke prevention in patients with 
atrial fibrillation (AF) the recommended dosage of apixaban is 5 mg taken orally twice 
daily, or 2.5-mg twice daily dose for those fulfilling at least two of the following clinical 
criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 133 µmol/L (8).  
 Apixaban undergoes multiple pathways of elimination, which include: renal 
excretion (renal clearance accounts for 27% of its total clearance (9)), metabolism, as well 
as intestinal and biliary excretion (10, 11). Not surprisingly, factors that influence these 
elimination pathways have been shown to alter the pharmacokinetics of apixaban in 
subjects, and ultimately drug exposure (12, 13).  For instance, individuals with impaired 
renal function exhibit lowered total clearance of apixaban and increased drug exposure 
such that subjects with mild, moderate, and severe renal impairment were associated with 
~16%, ~29%, and ~44% higher area-underneath-the-curve (AUC) values based on 
regression analysis, respectively (12).  Additional factors such as age and sex have shown 
to also influence the total clearance of apixaban, resulting in modest to low increases in 
drug exposure for subjects ≥65 years (32% higher AUC compared to those aged 18-40 
years) and females (15% higher AUC compared to males) (13), with a difference in renal 
function between groups also thought to be contributing to these effects. More recently, 
functional genetic polymorphisms within genes that code for proteins involved in the 
transport (ATP binding cassette [ABC] G2 gene) and metabolism (cytochrome P450 [CYP] 
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3A5 gene) of apixaban were shown to be associated with drug exposure, and altered 
apixaban clearance (14, 15).  
In terms of metabolism, apixaban is predominately hydroxylated by hepatic and 
intestinal cytochrome P450 3A enzymes (CYP3A4/5) (16, 17). Concomitant use of potent 
inhibitors and inducers of CYP3A4 such as ketoconazole and rifampin respectively, have 
been shown to alter apixaban AUC up to 50% (9, 18). In humans, 4β-hydroxycholesterol 
(4β-OHC) is an endogenous oxysterol that is created through the hydroxylation of 
cholesterol by CYP3A4 (19, 20).  Studies have demonstrated that changes in plasma 4β-
OHC concentrations correlate with changes in CYP3A4 activity driven by strong inducers 
and inhibitors of the enzyme (21, 22). Additional research has shown weak but significant 
correlation with other markers of CYP3A4 activity (midazolam (21, 23) and quinine/3-
hydroxyquinine (24)). As such, 4β-OHC concentration may serve as an additional predictor 
of interindividual variability in apixaban exposure. However, to date, the relationship 
between apixaban blood concentrations and endogenous markers of CYP3A activity 
among patients taking apixaban, has not been determined. Accordingly, in this study we 
examined plasma 4β-OHC concentration − an emerging biomarker of CYP3A activity − 
as a predictor of apixaban plasma concentration within AF patients. Furthermore, we 
examined 4β-OHC concentration in combination with factors that are known to impact 
apixaban exposure such as renal function, age, sex, weight, and common genetic variation, 
in an attempt to better explain the interindividual variation in FXaI concentration observed 
within our apixaban-treated cohort. 
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4.2 Methods 
4.2.1 Subjects and sample collection 
Study protocol was approved by the Research Ethics Board of the University of Western 
Ontario (London, Canada), and written informed consent was obtained from study 
participants. Our study cohort consisted of apixaban-treated atrial fibrillation patients 
obtained from a hospital setting as previously described (25), with a blood sample collected 
at steady-state during regular apixaban dosing intervals.  
 
4.2.2 Clinical and apixaban pharmacokinetic data 
Patient blood was taken at steady-state with the following data collected at the time of 
draw: apixaban dosing regimen (2.5 or 5 mg twice daily), hours post-dose, age, sex, weight, 
serum creatinine (µmol/L), estimated creatinine clearance (mL/min, calculated using 
Cockcroft-Gault equation), concomitant medications. Serum creatinine data was missing 
for 5 individuals. Single time point apixaban plasma concentrations used in this study were 
obtained from our previously reported dataset (25). 
 
4.2.3 Determination of 4β-hydroxycholesterol (4β-OHC) plasma 
concentration 
Picolinic acid derivatization and ultra-high-pressure liquid chromatography-tandem mass 
spectrometry (UHPLC-MS/MS) assay were used for measuring 4β-hydroxycholesterol 
(4β-OHC) as described by Honda et al. (26) with modifications. Both 4β-
hydroxycholesterol and 4β-hydroxycholesterol-d7 (internal standard) were obtained from 
Avanti Polar Lipids (Alabaster, AL) and dissolved in methanol at 1 mg/mL. All other 
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chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Calibration standards of 
4β-OHC (0, 5, 10, 20, 25, 30, 40, 50, 100, 200, 400, 800 ng/ml) were prepared in Krebs–
Henseleit bicarbonate buffer. Standard or plasma sample aliquots (50 µL) were saponified 
using 500 µL of ethanolic KOH containing 4β-hydroxycholesterol-(d7) at 10 ng/mL on a 
shaker for 1 hour. Water (150 µL) was added to samples then extracted twice in 750 µL of 
hexane, with the organic layer collected and evaporated to dryness in a Savant SpeedVac 
concentrator (Thermo Scientific). Afterwards, 170 µL of the following derivatization 
reagents were added to each sample and incubated at 80˚C for 1 hour: 2-methyl-6-
nitrobenzoic anhydride (100 mg), 4-dimethylaminopyridine (30 mg), picolinic acid (80 
mg), pyridine (1.5 µL), and trimethylamine (0.2 µL). Following the reaction, samples were 
once more extracted in 1 mL of hexane, and the organic layer was evaporated at 80˚C to 
dryness. Samples were reconstituted in 20 µL of NaCl dissolved in water (5 g/L) and 80 
µL of acetonitrile, then 20 µL of the resulting mixture were injected into the UHPLC-
MS/MS system. Chromatographic separation was performed using an Agilent 1290 
Infinity ultra–high pressure liquid chromatography system (Agilent Technologies, Santa 
Clara, CA) and an Agilent Zorbax Eclipse Plus C18 column (100 × 2.1 mm, 1.8 µm). 
Mobile phases used for gradient elution were 0.1% formic acid in water and 1:1 v/v 
acetonitrile:methanol. The mass analysis was performed on a TSQ Quantum triple-
quadrupole mass spectrometer (Thermo Scientific), while the following mass transition 
were monitored in positive mode for quantification: 4β-hydroxycholesterol, 635.4 → 146.5 
m/z; 4β-hydroxycholesterol-d7, 642.4 → 146.5 m/z. Interday variability on 3 separate days 
was 14.9%. 
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4.2.4 Single nucleotide polymorphism genotyping 
Genomic DNA was extracted from participant blood sample using the Gentra Puregene 
Blood Kit (Qiagen, Alameda, CA).  Genes encoding ABCB1, ABCG2, CYP3A4 and 
CYP3A5, were assessed based on established associations to apixaban metabolism and 
disposition (16, 17, 27), as well as 4β-OHC metabolism (CYP3A4 and CYP3A5 only) (24). 
Accordingly, TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA) 
were used to genotype patients for the following-reduced functional polymorphisms: 
CYP3A4 C>T Intron 6 (*22, rs35599367) (28), CYP3A5 g.6986A>G (*3, rs776746) (29), 
ABCB1 c.3435C>T (rs1045642), and ABCG2 c.421C>A (rs2231142). Hardy-Weinberg 
equilibrium was tested using χ2 method in GraphPad Prism 6 (La Jolla, USA). 
 
4.2.5 Data analysis 
Nonparametic Spearman’s correlation tests were performed to assess apixaban association 
with covariates 4β-OHC plasma concentrations, age, weight, estimated creatinine 
clearance (as shown in Figure 4-1 and Figure 4-2). Differences in 4β-OHC with respect 
to moderate CYP3A4 inhibitor use were assessed by Kruskal-Wallis multiple comparisons. 
Significance was defined as two-tailed p ≤ 0.05.  
Log (base 10)-transformed apixaban plasma concentration was used as the dependent 
variable in our multivariable linear regression analysis. We included the following 
independent variables: age, sex, weight, serum creatinine (µmol/L), 4β-hydroxycholesterol 
(ng/ml), concomitant P-gp and CYP3A4 inhibitor use, transporter or enzyme 
polymorphism, apixaban dosing regimen (2.5 or 5 mg twice daily), and hours post-dose. 
Rows containing missing data were removed from the dataset, as were  those patients who 
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were prescribed verapamil since there were too few patients to properly estimate the effect 
of this drug on apixaban concentration. This resulted in a dataset of 119 patients. We tested 
different genetic models for each genetic polymorphism – dominant, co-dominant, 
recessive, and additive models – and the model that best described the fit of apixaban 
plasma concentration was selected. With the exception of the ABCB1 c.3435C>T 
polymorphism, SNP genotypes were treated as binary variables (dominant model) with 
those that were homozygous wildtype coded as 0, and those that were heterozygous or 
homozygous variant coded as 1. ABCB1 c.3435C>T genotype was included as an additive 
model with those that were homozygous wild type, heterozygous, and homozygous variant 
coded as 0, 1, and 2, respectively. P-gp and CYP3A4 inhibitors, amiodarone and diltiazem 
were tested as separate binary variables, coded as 0 for non-users and 1 for users. Given 
that amiodarone and diltiazem use may have an effect on 4β-hydroxycholesterol 
concentration these variables were analyzed in separate models. We first regressed log 
(base 10) concentration onto dose, hours post-dose, age, sex, weight, serum creatinine, 4β-
hydroxycholesterol, and transporter or enzyme polymorphism. We repeated this with the 
same independent variables substituting 4β-hydroxycholesterol for amiodarone and 
diltiazem use. Two outliers were identified when examining the models’ residuals, the 
models’ R2 value improved after removing these outliers from the analysis. 
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4.3 Results 
4.3.1 Study population characteristics and allele frequencies 
We analyzed 4β-OHC plasma concentration data in 136 apixaban-treated AF patients with 
previously measured apixaban plasma concentration data (25). See Table 4-1 for summary 
of patient characteristics. Thirty-one percent of subjects were also on a P-gp and CYP3A4 
moderate inhibitor. Genotype and allele frequencies for the investigated ABCB1, ABCG2, 
CYP3A4, CYP3A5, polymorphisms are listed in Table 4-2 with all genotype frequencies 
within Hardy-Weinberg equilibrium.  
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Table 4-1. Study population characteristics 
 
  
Characteristic  
Subjects, n 136 
Age, median (IQR) 75 (65-82) 
Sex, Female (%) 46.3 
Weight, kg, median (IQR) 82.7 (69.6-97.3) 
BMI, kg/m2, median (IQR) 29.4 (24.6-34.0) 
Apixaban Dose 
 
     2.5 mg twice daily, (%) 53 (39.3) 
     5 mg twice daily, (%) 83 (61.5) 
Hours post dose, mean (min-max) 6.4 (3-11.9) 
Apixaban concentration, ng/ml, median (IQR) 187.6 (139.8-248.4) 
Concomitant P-gp and CYP3A4 Inhibitor use, (%) 30.8 
     Amiodarone, (%) 13.4 
     Diltiazem and Verapamil, (%) 17.4 
4β-hydroxycholesterol, ng/ml, median (IQR) 44.4 (28.8-71.1) 
Serum Creatinine, µmol/L, median (IQR) 91 (72-111) 
Creatinine Clearance, mL/min, median (IQR) ‡ 62.5 (47.7-93.6) 
Data represented as: percent of cohort (%), median (IQR, 25th and 75th percentile), 
mean (±SD). Abbreviations: BMI, body mass index; Lean body weight, LBW; IQR, 
interquartile range; SD, standard deviation. (‡) Creatinine clearance calculated using 
Cockcroft-Gault’s formula for patients with available serum creatinine. 
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Table 4-2. Allele frequencies for the ABCB1, ABCG2, CYP3A4, and CYP3A5 
polymorphisms 
 
Genotype No. of 
patients 
Genotype 
Frequency 
Allele 
frequency 
  
   
ABCB1 c.3435C>T  
 
54.7% 
     C/C 25 0.197 
 
     C/T 65 0.512 
 
     T/T 37 0.291 
 
ABCG2 c.421C>A  
 
12.8% 
     C/C 98 0.76 
 
     C/A 29 0.225 
 
     A/A 2 0.016 
 
CYP3A4 *22   
 
7.5% 
     C/C 109 0.858 
 
     C/T 17 0.134 
 
     T/T 1 0.008 
 
CYP3A5 *3   
 
94.6% 
     A/A 0 0 
 
     A/G 14 0.109 
 
     G/G 115 0.891 
 
 
 
 
  
 
 91 
4.3.2 4β-hydroxycholesterol plasma concentration 
We observed a 38.3-fold variation (minimum to maximum) in the measured plasma 4β-
OHC concentrations of our AF patients, with median of 44.4 ng/ml (13.5 - 131.6, 5-95th 
percentile). When comparing the 4β-OHC in relation to apixaban we found there was a 
statistically significant (p = 0.016, r  = -0.2063) weak inverse correlation between their 
measured plasma concentrations (Figure 4-1A). Apixaban concentrations did not 
significantly correlate (p = 0.2047) with 4β-OHC concentrations when they normalized to 
total cholesterol (Figure 4-1B).  
We also compared 4β-OHC concentrations of subjects that were taking moderate 
CYP3A4 and P-gp inhibitors to non-users (Figure 4-1C). Those taking diltiazem had 40% 
lower 4β-OHC concentrations compared to non-users (p < 0.0045), however, no significant 
difference was observed for amiodarone users. We did not observe a statistically significant 
difference in 4β-hydroxycholesterol plasma concentrations between wildtype and carriers 
of CYP3A4*22 and CYP3A5*3 alleles (data not shown).  
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Figure 4-1. Relationship between apixaban and 4β-hydroxycholesterol plasma 
concentrations. 
Association between apixaban (single time point) plasma concentrations with (A) 4β-OHC 
and (B) cholesterol normalized ratio. (C) Mean (±SD) 4β-OHC plasma concentrations in 
subjects taking concomittant CYP3A4 inhibitors compared to non-users. (D) Proposed 
mechanism for a assiocation between 4β-OHC, apixaban, and exogenous CYP3A4 
inhibitors. Abbreviations: 4β-OHC, 4β-hydroxycholesterol; r, Spearman correlation 
coefficient; p, p-value. 
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4.3.3 Apixaban plasma concentration 
We assessed the correlation between apixaban plasma concentration and the clinical factors 
used for dose selection. After normalizing for dosage, apixaban plasma concentrations 
positively correlated with increasing age (r = 0.3455, p < 0.0001) and increasing serum 
creatinine (r = 0.3416, p < 0.0001) (Figure 4-2A-B). While patients that weighed less 
appeared to have higher drug concentrations, this was not statistically significant (Figure 
4-2C). Furthermore, plasma concentrations were found to correlate more with Cockcroft-
Gault’s estimated creatinine clearance (r = -0.4984, p < 0.0001; Figure 4-3), a formula 
used to estimate glomerular filtration rate using age, serum creatinine, weight, and sex.
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Figure 4-2. Relationship between and apixaban and clinical factors used for dose selection. 
Dose-normalized apixaban (single time-point) plasma concentrations versus clinical factors used for apixaban dosing: (A) age, (B) 
serum creatinine, (C) serum creatinine. Abbreviations: r, Spearman correlation coefficient; p, p-value. 
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Figure 4-3. Relationship between apixaban and estimated creatinine clearance. 
Dose-normalized apixaban (single time-point) plasma concentrations versus estimated 
creatinine clearance. eCrCl was calculated using Cockcroft-Gault’s formula.  
Abbreviations: eCrCl, estimated creatinine clearance; r, Spearman correlation coefficient; 
p, p-value. 
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4.3.4 Multivariable linear regression analysis  
Multivariable linear regression analysis was carried out to assess the relative contribution 
of 4β-OHC as determinant of apixaban plasma concentration while controlling for clinical 
variables (age, sex, weight, serum creatinine, apixaban dose, hours post dose) as well as 
genetic polymorphisms in CYP3A4, CYP3A5, ABCB1, and ABCG2. Our regression 
analysis indicated higher 4β-OHC concentrations were associated with lower apixaban 
concentrations, even after controlling for these covariates (p = 0.001; Table 4-3). The 
adjusted r2 value (percent explained) of the model was 0.279. Higher apixaban 
concentrations were associated with increased age (p = <0.001), female sex (p = 0.014), 
and elevated serum creatinine (p = <0.001). Hours post dose, weight, diltiazem use, as well 
as CYP3A4*22, CYP3A5*3, ABCB1 c.3435C>T, or ABCG2 c.421C>A carrier status 
were not significant predictors (p > 0.05) of apixaban plasma concentration in our cohort. 
Ultimately, the addition of 4β-OHC as a variable increased the variation explained by 7.3% 
(27.9% versus 20.6% total variation explained) compared to a model with only clinical and 
genetic variables (Figure 4-4).  
The effect of amiodarone and diltiazem use were assessed in a separate regression 
model excluding 4β-OHC (Figure 4-4). The results of this analysis indicated amiodarone 
use (p = 0.014) and by not diltiazem use to be associated with higher apixaban plasma 
concentration (Appendix C). This model explained 23.5% of interpatient variation in 
apixaban plasma concentration. 
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Table 4-3. Multiple linear regression coefficients for apixaban plasma concentration 
in atrial fibrillation patients (n = 119). 
 
Predictor variable B 95% CI P-value 
Dose  0.111 0.076, 0.146 <0.001 
Hours post dose -0.013 -0.031, 0.005 0.152 
Age, years 0.007 0.003, 0.011 0.001 
Sex, Female 0.092 0.019, 0.166 0.014 
Weight, kg -0.001 -0.003, 0.001 0.461 
Serum creatinine,  µmol/L 0.002 0.001, 0.003 <0.001 
ABCB1 c.3435C>T , per allele 0.002 -0.046, 0.051 0.925 
ABCG2 c.421C>A, 1 or 2 allele 0.068 -0.009, 0.145 0.083 
CYP3A4*22, 1 or 2 allele 0.010 -0.084, 0.103 0.837 
CYP3A5*3, 1 or 2 allele 0.016 -0.092, 0.124 0.771 
4β-Hydroxycholesterol, ng/ml -0.001 -0.002, -0.001 0.001 
Adjusted R squared for model, 0.279 
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Figure 4-4. Interpatient variation in apixaban plasma concentration explained by 
clinical variables, genetic polymorphisms, and 4β-hydroxycholesterol 
Nested model comparing the percent of interpatient variation in apixaban plasma 
concentration explained with or without including 4β-Hydroxycholesterol. (‡) Model 1 
including independent variables: dose, hours post dose, age, sex, weight, serum creatinine, 
as well as CYP3A4, CYP3A5, ABCB1, and ABCG2 genotype. 
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4.4 Discussion 
Apixaban is primarily oxidized by CYP3A enzymes (14, 15). Accordingly we examined 
plasma 4β-OHC concentration − an emerging biomarker of CYP3A activity − as a 
predictor of interindividual variability in apixaban plasma concentration among AF 
patients. We found a weak, but statistically significant correlation between plasma 
concentrations of apixaban and 4β-OHC, with higher 4β-OHC concentrations (higher 
CYP3A4 activity) associated with lower apixaban concentrations (Figure 4-1, Table 4-3). 
Even though the majority of the interindividual variation in apixaban concentration 
remained unexplained (~72%), including 4β-OHC along with clinical variables in our 
multivariable linear regression analysis improved the variation explained by 7% (28% 
versus 21%) (Figure 4-4), when compared to a model with clinical variables alone. 
Interestingly, 4β-OHC:cholesterol (cholesterol normalized ratio) did not show any 
statistically significant  correlation with apixaban concentration.  
4β-hydroxycholesterol (4β-OHC) is one of the dominate oxysterols present in the 
human circulation at concentrations 103-104 times lower than total cholesterol with a 
reported half-life ≥ 60 hours  (30, 31). The role of CYP3A4 in the hydroxylation of 
cholesterol to 4β-OHC was demonstrated in the early 2000s by Bodin and colleagues 
through in vitro incubation of cholesterol with recombinant CYP enzymes (CYP3A4, 
CYP1A2, CYP2C9, CYP2B6) (32). Among the enzymes tested, 4β-OHC formation was 
found only with CYP3A4. This effort came after the discovery that patients taking 
carbamazepine, phenytoin, and phenobarbital (strong inducers of CYP3A) experienced an 
≥ 20-fold increase in plasma 4β-OHC concentration (32). Since then, many studies have 
shown that changes in 4β-OHC correlate well with changes in CYP3A activity that are 
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driven by strong CYP3A inducers (19, 23, 33-35) and inhibitors (35-37), with 4β-OHC 
increasing and decreasing from baseline, respectively. In our study, subjects that were 
taking the moderate inhibitor, diltiazem (n = 22), had significantly lower 4β-OHC 
concentration (40% lower compared to non-users, n = 94). However, no difference was 
seen in amiodarone users, which is consistent with diltiazem having greater evidence for a 
CYP3A4 inhibitory effect compared to amiodarone (38, 39).  
The evidence surrounding 4β-OHC supports its utility for assessing changes in the 
CYP3A activity that are driven by strong CYP3A inhibitors and inducers. On the other 
hand, its usefulness as a marker of basal CYP3A activity is yet to be fully established (40). 
Current evidence shows a weak correlation between 4β-OHC concentrations and 
previously recognized markers of CYP3A activity (midazolam (21, 23) and quinine/3-
hydroxyquinine (24)), but its association with other exogenous CYP3A substrates have 
produced mixed results. In an study looking at anticancer drug, docetaxel (largely 
metabolized by CYP3A4), the authors found 4β-OHC to have limited predictive value 
towards docetaxel clearance, with a correlation between 4β-OHC concentration and 
clearance seen only in males  (r = .35, p = 0.01) (41). Our group has previously reported a 
relationship between 4β-OHC and plasma concentrations of the lipid-lowering drug, 
atorvastatin, also known to be metabolized by CYP3A4 (42). Taken together, the degree 
of association between 4β-OHC and exogenous substrates is more than likely complicated 
by factors other than CYP3A that include, but are not limited to: differences solubility and 
permeability, intestinal versus hepatic metabolism, and substrate specificity to intestinal, 
hepatic, or renal transporters. 
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Although CYP3A-mediated metabolism is an elimination pathway for apixaban, it 
is not the only way that this drug is cleared from the body. In a mass-balance study with 
healthy subjects, only ~30% of the recovered apixaban dose (after oral administration) was 
in metabolite form (10). This may reflect why 4β-OHC was observed to have a marginal 
effect in explaining the variation of apixaban plasma concentration among our AF patients.  
Kidney function and age were the strongest predictors of variation in apixaban 
concentration among our AF cohort. The correlation of apixaban plasma concentration 
with serum creatinine (Figure 4-2B, Table 4-3) and estimated creatinine clearance (Figure 
4-3) that we observed is consistent with phase I study results, which showed worsening 
renal impairment correlated with reduced total clearance and increased AUC.  Furthermore, 
our observation of higher apixaban concentration being associated with increased age 
(Figure 4-2A, Table 4-3) and female sex (Table 4-3), were also consistent with previous 
studies involving healthy (13), AF (14), and VTE (43) subjects. Although extremes in body 
weight (≤ 50 kg or ≥120 kg) have previously been shown to influence apixaban exposure 
(44), weight was not a predictor of variation in apixaban concentration among our patients. 
This likely due to the fact that only 12% of our patients were ≤ 50 kg or ≥120 kg. In addition 
to the CYP3A enzymes, apixaban is a known substrate of ATP binding cassette (ABC) 
efflux transporters, P-glycoprotein (P-gp, ABCB1) and Breast Cancer Resistance Protein 
(BCRP, ABCG2) (14, 15). While we did not observe an association between carrier status 
of common functional genetic polymorphisms and variability in apixaban plasma 
concentration, recent work in a Japanese AF population report the ABCG2 421A/A 
genotype to be associated with higher trough apixaban plasma concentrations and reduced 
clearance, whilst the CYP3A5*1/*1 genotype was seen to be associated with lower trough 
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concentration and higher clearance (14, 15). This discrepancy is likely due to the 
differences in the allele frequencies that are exist between the different ethnic populations 
(Ueshima et al. allele frequencies were 33% and 78% for ABCG2 421C>A and CYP3A5*3 
respectively). The effect of genetic variation may have been observed had there been more 
variant carriers in our study. 
In summary, our results are consistent with what is known about the CYP3A4-
mediated metabolism of apixaban and 4β-OHC formation. Even though the clinical factors 
used for dose selection, such as age and serum creatinine, accounted for the majority of the 
explainable variation in apixaban plasma concentration, our findings suggest that CYP3A4 
activity can be used as an additional predictor of interindividual variability of apixaban 
exposure. Indeed, further investigations correlating 4β-OHC as well as other markers of 
CYP3A4 activity with parameters of apixaban exposure (i.e., AUC, trough plasma 
concentrations) and clearance are warranted to confirm the degree to which CYP3A4 
activity influences apixaban exposure. 
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5 Identification of rare or patient-specific single 
nucleotide variants as potential determinants of 
apixaban disposition using a custom targeted 
next-generation exome sequencing approach 
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5.1 Introduction 
In Chapter Four, we noted that known common genetic variation in metabolizing enzymes 
and efflux transporters (CYP3A4*22, CYP3A5*3, ABCB1 c.3435C>T, or ABCG2 
c.421C>A) were not significant predictors of the interpatient variation in apixaban 
concentration observed in our AF cohort. Furthermore, a large proportion (~72%) of this 
variation remained unaccounted for within our regression analysis.  It is our hypothesis that 
rare or patient-specific single nucleotide variations within certain individuals are likely 
contributing to this variability.  
 While previous pharmacogenetic research has focused on evaluating common 
functional variation, more recent large-scale whole genome or exome sequencing studies 
have revealed that humans harbor a large number of rare, potentially deleterious variants 
in many of these pharmacogenes (1, 2). Specifically, the analysis of sequencing data for 
146 pharmacogenes combining about 7500 individuals of the Exome Sequencing Project 
(ESP) (3) and the 1000 Genomes Project (1000G) (4) indicated that more than 90% of all 
recorded single nucleotide variants (SNVs) were rare with a minor allele frequency (MAF) 
below 1%, and that 30-40% of the predicted functional variability was associated with 
these rare variants (1). Further studies also support that rare SNVs in drug processing or 
drug target genes significantly contribute to interpatient differences in drug disposition and 
response beyond established common genetic predictors as shown for CYP2C9 and 
warfarin dose requirement (5, 6) and SLCO1B1 and methotrexate clearance and toxicity 
(7).  
Targeted next-generation sequencing (NGS) represents a new time- and cost-
effective technology for detecting common and rare genetic variation, allowing for DNA 
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enrichment of entire exomes or coding exons of select genes coupled with massive parallel 
sequencing of the enriched product. Through the application of this method, particularly, 
in those apixaban-treated AF subjects who demonstrated unexpectedly high drug plasma 
concentrations, we would be able to better identify those individuals with rare SNVs that 
result in aberrant function or expression of their CYP enzyme or transporter, consequently 
impacting their apixaban exposure. 
Therefore, we created a NGS-based exome capture panel (PGxSeq) capable of 
detecting common and clinically established, as well as rare and potentially functional 
genetic variation within 100 pharmacogenes, including seven genes (ABCB1, ABCG2, 
CYP3A4, CYP3A5, POR, NR1H4, NR1I2) that are relevant to apixaban disposition. Our 
objectives were to: 1) evaluate the sequencing performance as well as the accuracy of 
variant discovery within a validation cohort (n = 48); 2) evaluate the identified variation in 
all 100 pharmacogenes with respect to population allele frequencies and predicted 
functional effects for a larger cohort (n = 245); 3) apply this method for SNV discovery in 
a small exploratory cohort of apixaban-treated AF patients who exhibited FXaI plasma 
concentrations exceeding the maximum concentration observed during clinical trials while 
being dosed according to product monograph (test group n = 6, control n = 6). 
 
5.2 Methods 
A flow diagram of the sample and data processing can be found in Figure 5-1. A detailed 
methods description can be found in Appendix D. 
 
 
  
 
 110 
 
 
Figure 5-1. Sample and data processing workflow. ‡  
One subject was sequenced twice to obtain higher sample depth-of-coverage. 
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5.2.1 Study population 
NGS was carried out in a total of 245 Caucasian subjects, for which genomic DNA was 
obtained from a venous blood sample following written informed consent. Sequencing 
performance and accuracy of variant detection was evaluated in the first 48 subjects − this 
was our validation cohort. Following this, all 245 subjects were used to evaluate genetic 
variation in terms of population allele frequencies and predicted functional effect. Then we 
carried out candidate gene SNV discovery in a subgroup of 12 apixaban-treated AF patients 
(described below) with a known apixaban drug concentration phenotype. This study was 
approved by the Research Ethics Board of Western University, London, Canada. 
 
5.2.2 Apixaban cohort 
Twelve individuals from this previous study were included as part of the n = 245 
participants sequenced in this study, and consisted of two different apixaban plasma 
concentration phenotypes: high concentration (test group, n = 6) and normal concentration 
(control group, n = 6). Specifically, apixaban phenotype was determined based on whether 
the patient’s measured apixaban plasma concentration fell within the range of 41 - 321 
ng/mL, representing the lower limit for C
min (5
th percentile) to the upper limit for C
max (95
th 
percentile), respectively, for an individual on apixaban 5 mg twice daily at steady state as 
previously described (refer to Chapter Four). Concentrations above this range were 
considered high, while those within were considered normal. The inclusion criteria for both 
groups was that patients were dosed according to product monograph, and did not meet 
any of the clinical factors used for dose reduction that are known clinical predictors of 
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higher apixaban exposure (age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 133 
µmol/L)(8). 
Our goal was to discover rare or patient specific hypothesis generating single 
nucleotide variations among candidate genes involved in the metabolism or transport of 
apixaban that potentially correlate with apixaban concentration phenotype. The candidate 
genes analyzed were selected based on the following evidence: 1) the gene product 
interacts directly with apixaban as a transporter (ABCB1, ABCG2) or metabolizing enzyme 
(CYP3A4, CYP3A5); or 2) the gene product is involved in regulating the expression 
(NR1H4, NR1I2), or is required for the function (POR) of an enzyme or transporter that 
interacts directly with apixaban. 
 
5.2.3 Gene selection, capture probe design and enrichment 
method 
DNA enrichment was carried out using the Nextera Rapid Capture Custom Enrichment Kit 
(Illumina, San Diego, CA) comprising of 100 genes including major cytochrome P450 
(CYP) enzymes, phase II conjugation enzymes, drug transporters of the solute carrier 
(SLC) and ATP binding cassette (ABC) families as well as regulatory proteins. In addition, 
regions encompassing 14 known functional promoter or intronic SNVs were included. 
Capture probes were custom-designed using the Illumina Design Studio (Illumina, San 
Diego, CA) comprising of 722 kilobases (kb) with 4% overlap. DNA library preparation 
and target-capture sequencing was conducted at the London Regional Genomics Center, 
London, Ontario, as previously described (9). 
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5.2.4 Base calling, sequence alignment, coverage analysis and 
variant detection 
Alignment of sequencing reads and variant calling were performed using the CLC Bio 
Genomics Workbench 7.0 (CLC Bio, Aarhus, Denmark) through a custom-automated 
workflow. Coverage analysis in the validation cohort and variant detection in all 245 
subjects was restricted to coding regions plus 10-bp before and after each exon and 250-bp 
of 5’ and 3’ UTR, and targeted promoter or intronic SNVs. 
 
5.2.5 Variant annotation and in silico prediction 
Functional annotation of SNVs was carried out using ANNOVAR (10) through in silico 
prediction algorithms (Combined Annotation Dependent Depletion [CADD] (11), Sorting 
Intolerant from Tolerant [SIFT] (12), and PolyPhen-2 (13)), and population frequency 
determined through linkage with genomic databases (RefSeq, dbSNP137, 1000G, Exome 
Aggregation Consortium [ExAC];  obtained July 8, 2015). Potentially functional SNVs (or 
deleterious) were considered with a score of  >20 for CADD (scaled) (11), <0.05 for SIFT 
(12), or >0.85 for PolyPhen-2 (13). Variants were classified as non-synonymous, 
synonymous, insertion or deletion (in-del; frameshift, non-frameshift), splicing, stop gain 
or loss, or known functional intronic/ promoter variants as non-coding. Coding variants 
were further grouped by MAF reported in the ExAC database as common (MAF ≥ 5%), 
low frequency (1% ≤ MAF > 5%), or the combined category of rare (MAF < 1%) and novel 
(absent from ExAC and dbSNP137). In silico functional assessment was restricted to 
protein-coding and gain- or loss-of-a-stop codon SNVs. 
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5.2.6 Concordance assessment 
In our validation cohort, orthogonal genotyping was performed using TaqMan allelic 
discrimination for 32 functionally validated or clinically actionable SNVs. Rare NGS 
variants were confirmed retrospectively by Sanger sequencing within 4 pharmacogenes. 
Sanger sequencing methods and TaqMan assay IDs are listed in Table S2, Appendix D, 
and Table S3, Appendix D, respectively. 
 
5.2.7 Statistical analysis 
Analyses were performed using R (14) and GraphPad Prism 6 (La Jolla, USA). Differences 
in the proportion of possibly deleterious variants grouped by frequency was assessed using 
Chi-squared test, and Pearson correlation coefficient used to determine the association 
between allele frequencies in our study compared to 1000 Genomes and ExAC database. 
Statistical significance was defined as P<0.05. 
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5.3 Results 
5.3.1 Sequencing performance and accuracy of variant detection 
in the validation cohort 
Performance parameters by sequencing run for the first 48 subjects are presented in Table 
5-1. The total number of sequenced reads per run ranged from 20.0 to 27.6M reads, with 
87.1 to 89.2% of reads passing Illumina control filters (Reads PF). The mean per base 
quality score (Phred quality score, Q) for Reads PF were ≥30, indicating a miscall error 
rate in base calling of less than 0.1% (or 99.9% sequencing accuracy) up until the 150 bp 
read position. A decline in base quality was observed beyond 150 bp likely due to a 
combination of short fragment length with the 2 x 300 bp chemistry used for DNA library 
preparations (Figure S1, Appendix E). Consequently, the threshold for variant detection 
was set to Q ≥ 30 to minimize false-positive variant calls. After de-clustering each run, 
sequencing data for each sample were assessed for read count, base quality, and guanine 
(G) and cysteine (C) distribution (Figure 5-1). Three samples had a mean GC content of 
up to 65%, exceeding the expected range of 45-50% (15) (Figure S2, Appendix E).  
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Table 5-1. Overview of sequencing performance parameters in our validation cohort 
separated by run cluster. 
 
  Run 1 Run 2 Run 3 
Raw sequencing parameters (n = 48) 
   
Subjects, n 12 12 24 
Cluster density, (1000/mm2) 841 1149 1183 
Total reads, (106)  20 27.1 27.6 
Reads PF, (106) 17.8 23.9 24 
Reads PF, (%) 89.2 88.2 87.1 
Mapping parameters (422 kb)  
   
Subjects, n  12 12 24 
Reads PF mapped to hg19 genome (106) 
   
per sample 1.2 1.6 1 
DOC, mean (- duplicates removed) 187.3 ª 297.7 ª 127.9 ª 
DOC, median (- duplicates removed) 187 ª 303 ª 126 ª 
Bases with mean DOC <30x, (%) 2.4 ᵇ 1.8 ᵇ 3.3 ᵇ 
Reads PF, reads passed filter; DOC, depth of coverage. ª Calculated for samples 
across the 422 kb target sequence; ᵇ Calculated as percent of 422 kb target 
sequence. ‡ Excluding one sample with low read count (< 2500 reads). 
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We next assessed the depth-of-coverage (DOC), defined as the number of overlapping non-
duplicate reads mapped to the reference genome, across the target sequence separated by 
sequencing cluster (n = 12 or 24). As expected, samples in the smaller cluster had a greater 
mean DOC per subject (range 183 – 298×) compared to those sequenced in the larger 24 
DNA sample cluster (128×) (Table 5-1). Despite these differences, the percent bases with 
a mean DOC < 30× was comparable ranging from 1.8% - 3.3%. When evaluated on a gene-
by-gene basis (Figure 5-2), 98 of the 100 genes on our panel had a mean DOC ≥ 80×. 
Among all genes, the glutathione S-transferase (GST) genes showed the lowest DOC per 
subject (min-max; 14.1 - 233× for GSTM1; 5.5 - 267× for GSTT1). Carboxylesterase 1 
(CES1) had the highest proportion of targeted regions < 30×, largely due to lack of 
coverage for exons 12 to 14, followed by carbonyl reductase 3 (CBR3), and CYP1A2 
(Figure S3, Appendix E). The remaining genes of Phase I and II enzymes, ABC and SLC 
transporters, nuclear receptors, and drug targets had ≥ 95% of their target region at DOC > 
30×. Intra-subject variability in DOC was greatest in the 3 DNA samples with high GC 
content (Figure S4, Appendix E).  
Utilizing TaqMan assays for 32 validated or clinically actionable SNVs in our 
validation cohort (Table 5-2.), we observed 100% concordant between TaqMan derived 
versus NGS derived genotypes, confirming heterozygous and homozygous carrier status. 
Using Saner sequencing we were able to confirm all five rare coding variants that were 
identified by NGS (Table 5-2.).
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Depth-of-coverage (DOC) by gene separated by size of sequence cluster (n=12 or 24). ‡ For UGT1A4, UGT1A6, UGT1A8, and 
UGT1A9, the first exon was included to calculate DOC while shared exons were assessed only once with UGT1A1. Data are 
shown as mean ±SD
C
YP
3A
7
C
YP
2J
2
C
ES
1
C
B
R
1
C
YP
3A
5
C
ES
4A
A
O
X1
FM
O
1
C
YP
4F
2
C
YP
2C
8
C
YP
1A
1
C
YP
2C
19
P
O
N
1
N
Q
O
1
FM
O
3
C
YP
3A
4
C
YP
2B
6
FM
O
2
P
O
R
C
YP
1B
1
C
ES
2
C
YP
2D
6
C
YP
2C
9
C
YP
1A
2
C
B
R
3
‡ U
G
T1
A
4
‡ U
G
T1
A
6
‡ U
G
T1
A
8
‡ U
G
T1
A
9
N
A
T2
N
A
T1
U
G
T2
B
7
‡ U
G
T1
A
1
U
G
T2
B
15
TY
M
S
C
O
M
T
SU
LT
1A
1
TP
M
T
G
S
TP
1
U
G
T2
B
17
TY
M
P
G
S
TT
1
G
S
TM
1
0
100
200
300
400
500
D
O
C
Cluster of 12 (n = 24)
Cluster of 24 (n = 24)
AB
C
C
2
AB
C
C
5
AB
C
C
3
AB
C
B
1
AB
C
C
1
A
B
C
B1
1
AB
C
C
4
A
B
C
G
2
SL
C
22
A
8
SL
C
51
A
SL
C
O
2B
1
SL
C
10
A
1
SL
C
47
A
2
SL
C
10
A
2
SL
C
22
A
1
SL
C
47
A
1
SL
C
22
A
2
SL
C
22
A
9
SL
C
15
A
2
SL
C
51
B
SL
C
22
A
7
SL
C
22
A
4
SL
C
31
A
1
SL
C
22
A
6
SL
C
15
A
1
SL
C
O
1B
3
SL
C
22
A
3
SL
C
19
A
1
SL
C
O
1A
2
SL
C
O
1B
1
SL
C
O
1B
7
N
R
1I
3
N
R
1I
2
N
R
1H
3
N
R
1H
4
VD
R
H
N
F4
A
PP
A
R
a
H
N
F1
A
A
R
N
T
N
R
1H
2
P
P
A
R
g
A
hR
AD
R
B
2
C
D
A
M
TH
FD
1
D
R
D
2
A
M
PD
1
A
TI
C
M
TH
FR
IT
P
A
D
PY
D
VK
O
R
C
1
FP
G
S
G
G
H
AD
R
B
1
D
H
FR
0
100
200
300
400
500
D
O
C
0%
20%
40%
Percent of targeted bp 
below 30-fold DOC
0%
20%
40%
Phase I Metabolism Enzymes Phase II Metabolism Enzymes
Transporter 
ABC family
Transporter 
SLC family
Nuclear receptors Other
Enzymes/Receptors
    Figure 5-2. Depth of coverage per gene. 
 
 119 
Table 5-2. Concordance rate (%) of genotypes between NGS data and TaqMan or Sanger validated genotypes in the 
validation cohort (n = 48). 
 
Gene Allele Polymorphism Effect/ dbSNP137 Study 1000G EXaC Patients Concordance    
Location 
 
(n=245) EUR 
 
tested 
 
     
AF AF AF HET HOM (%)ª 
A. Concordance of common and/or clinically relevant SNPs with TaqMan genotyping   
ABCB1 
 
c.3435 C>T p.I1145I rs1045642 0.47 0.47 0.50 11 3 100 
ABCC2 
 
c.1249 G>A  p.V417I rs2273697 0.18 0.20 0.20 5 2 100 
ABCG2 
 
c.421 C>A p.Q141K rs2231142 0.11 0.10 0.12 10 3 100 
ABCG2 
 
c.34 G>A p.V12M rs2231137 0.04 0.06 0.11 2 - 100 
CYP2B6 
 
c.1459 C>T  p.R487C rs3211371 0.12 0.10 0.09 8 1 100 
CYP2B6 *9 c.516 G>T p.Q172H rs3745274 0.22 0.23 0.27 5 2 100 
CYP2C19 *17 c.-806 C>T promoter rs12248560 0.22 0.23 NA 8 3 100 
CYP2C19 *2 c.681 G>A p.P227P rs4244285 0.14 0.15 0.19 4 1 100 
CYP2C9 *2 c.430 C>T p.R144C rs1799853 0.13 0.12 0.09 7 2 100 
CYP2C9 *3 c.1075A>C p.I359L rs1057910 0.06 0.06 0.06 5 - 100 
CYP2D6 *3A g.2549 A>del p.R208fs rs35742686 0.03 0.02 0.01 2 - 100 
 
 120 
CYP2D6 *4 g.1846 G>A splice rs3892097    0.19 0.19 0.17 16 4 100 
CYP2D6 *9 c.688_690AAG>del p.K281del rs5030656 0.02 0.02 0.02 1 - 100 
CYP2D6 *10 g.100 C>T p.P34P rs1065852 0.22 0.20 0.25 18 4 100 
CYP2D6 *41 g.2988 G>A intronic rs28371725 0.12 0.09 0.08 10 1 100 
CYP3A4 *22 c.522-191 C>T intronic rs35599367 0.05 0.05 NA 7 - 100 
CYP3A5 *3 g.6986 A>G splice rs776746 0.06 0.95 NA 6 - 100 
CYP4F2 *3 c.1297 C>T p.V433M rs2108622 0.30 0.27 0.27 6 3 100 
DPYD 
 
c.2846 A>T p.D949V rs67376798 0.02 0.0022 0.0026 1 - 100 
NR1H4/FXR 
 
c.-1 G>T 5' UTR rs56163822 0.03 0.02 0.08 4 - 100 
NR1H3/LXRɑ 
 
c.297 C>T p.S547S rs2279238 0.16 0.16 0.25 6 2 100 
POR 
 
c.1508 C>T p.A503V rs1057868 0.26 0.30 0.36 5 2 100 
NR1I2/PXR 
 
g.39823 C>T intronic rs2276707 0.20 0.17 0.24 9 - 100 
SLCO1B1 *1b c.388 A>G p.N130D rs2306283 0.39 0.40 0.48 9 4 100 
SLCO1B1 *5 c.521 T>C p.V174A rs4149056 0.17 0.17 0.13 9 2 100 
SLCO1B3 
 
c.699 G>A p.M233I rs7311358 0.80 0.85 0.80 5 16 100 
 
 121 
SLCO2B1 
 
c.935 G>A p.R290Q rs12422149 0.07 0.10 0.17 7 - 100 
TPMT *3A c.460 G>A p.A154T rs1800460 0.04 0.03 0.03 4 - 100 
TPMT *3B c.719 A>G p.Y240C rs1142345 0.04 0.03 0.04 4 - 100 
VDR 
 
g.1270 G>A intergenic rs11568820 0.17 0.23 NA 3 1 100 
VDR  g.47906043 T>C intergenic rs4516035 0.43 0.43 NA 8 7 100 
VKORC1 
 
c.-1639 G>A intergenic rs9923231 0.39 0.40 NA 5 6 100 
B. Concordance of rare variation in select genes by Sanger sequencing  
ABCB1 
 
c.3320 A>C p.Q1107P rs55852620 0.012 1.0E-02 6.1E-03 1 - 100 
CYP2D6 
 
c.A818C p.H273P rs5030867 0.002 NA 0.0013 1 - 100 
SLCO1B1 c.850 A>C p.N284H novel 0.002 NA 4.1E-05 1 - 100 
SLCO1B1 
 
c.1159 G>A p.A387T novel 0.002 NA 1.7E-05 1 - 100 
SLCO1B3 
 
c.287 T>G p.L96X novel 0.002 NA NA 1 - 100 
(ª) Percentage of total tested DNA samples with NGS-determined genotypes concordant with TaqMan or Sanger derived genotypes. 
Abbreviations: AF, allele frequency; dbSNP 137, Single Nucleotide Polymorphism database build 137; ExAC, Exome Aggregation 
Consortium version 0.3; HET, heterozygous genotype; HOM, homozygous genotype; 1000G EUR, 1000 Genomes Project European dataset; 
NA, not found in dbSNP 137, 1000G EUR, or ExAC database, respectively
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5.3.2 Analysis of variants in pharmacogenes 
Genetic variation was assessed in 245 Caucasians (Figure 5-1, 5-3), and the SNVs 
identified presented in Figure 5-3 according to functional effect, number of variants per 
gene, or reported MAF in  ExAC (if exonic). A total of 1089 unique SNVs were identified, 
consisting of 605 non-synonymous (55.6%), 409 synonymous (37.6%), 13 splice-site 
(1.2%), 13 stop gain or loss (1.2%), and 37 insertion-deletions (21 frameshift, 16 non-
frameshift; 3.4%), as well as 12 known non-coding SNVs (1.0%) (Figure 5-3A). The 
majority of variants (71%) were present only in heterozygous form. Among exonic variants 
(Figure 5-3B), 25.9% of SNVs were common (ExAC MAF >5%), 14.2% occurred at a low 
frequency (ExAC MAF ≥1 and 5), whereas 59.9% were either rare or novel (ExAC MAF 
<1% or absent from ExAC or dbSNP137). MAFs in this study largely mirrored those 
reported in much larger data sets (ExAC, 1000G) (Figure S5, Appendix E. According to 
gene family or drug-related function, the CYP gene families had the most variants per 
targeted base pairs, followed by the UDP glucuronosyltransferases (UGT) and ABC family, 
then SLC family, while nuclear receptors were the least variable (Figure 5-3C). 
Individually, among Phase I enzymes, CYP2D6 had the highest total number of SNVs (54) 
and the highest number of rare or novel variants from our gene panel (Figure 5-3D), and 
UGT1A4 had the most SNVs among Phase II enzymes. Within the SLC family, organic 
cation transporter 1 (SLC22A1) showed the highest number of SNVs as well as rare or novel 
SNVs among all SLC genes sequenced. Among transporter genes of the ABC family, 
ABCC2 had the highest number of the SNVs with 34 variants.  
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Figure 5-3. Analysis of variation in 245 subjects. 
Analysis of genetic variation in 245 subjects assessed by PGxSeq. SNVs according to 
functional effect (A), allele frequency reported in ExAC database (B), number of exonic 
variants per target region (C), or gene (D). ‡ For UGT1A4, UGT1A6, UGT1A8, and 
UGT1A9, only SNVs located within the first exon were counted while shared exons were 
assessed only once with UGT1A1. ExAC, Exome Aggregation Consortium; MAF, minor 
allele frequency; SNV, single nucleotide variant. 
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5.3.3 In silico assessment of variants in pharmacogenes 
Potential functional effects of the identified non-synonymous variants were assessed with 
CADD, PolyPhen-2, and SIFT. Our results showed marked differences between the 
prediction scores derived from these algorithms (Figure 5-4). However, the proportion of 
rare (MAF < 1%) or novel variants that were categorized as possibly deleterious was greater 
than the proportion of common (≥ 5%) or low frequency (≥ 1-5%) variants for all 3 tools 
(CADD: p = 0.0004, PolyPhen-2: p = 0.0013, and SIFT: p = 0.0076, Figure S6, Appendix 
E). The majority of pharmacogenes (87 out of 100) harbored at least one variant with a 
CADD score > 20 (median, 2). Rare or novel variants that were predicted as deleterious 
(CADD score > 20) were almost entirely observed in heterozygous form, with a median of 
two SNVs per subject (min-max, 0 - 8)  across the 100 genes (Figure S7, Appendix E). 
Conversely, nearly all subjects (244 out of 245) had ≥ 1 common deleterious variant(s) in 
the homozygous form, median three (0 - 11) SNVs per subject. Finally, we assessed 
prediction scores among 12 CYP genes that account for the majority of known drug 
oxidation reactions (Figure S7, Appendix E); on average, 15.8% (5 - 95th percentile, 9.1 - 
20.4%) of SNVs with a CADD > 20 among individuals were located within these gene. 
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Figure 5-4. In silico assessment of non-synonymous variants in pharmacogenes. 
In silico assessment of non-synonymous variants in pharmacogenes identified by PGxSeq (N = 245). (A) Frequency distribution 
of variants according to SIFT, PolyPhen-2, and CADD scores separated by minor allele frequency reported in the ExAC database. 
Shaded regions represent the proportion of potentially functional variants (or deleterious), defined as a scaled CADD score > 20 
(11), a SIFT score < 0.05 (12), or a PolyPhen-2 score > 0.85 (13)
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5.3.4 Variation in genes of clinical relevance  
Among 9 clinically relevant genes for which Clinical Pharmacogenetics Implementation 
Consortium (CPIC) prescribing guidelines for specific variant-drug combinations have 
published, there are 29 “Level 1A/1B” variants categorized as having strong evidence for 
influencing drug efficacy/response and prescribing recommendations 
(https://cpicpgx.org/alleles/, accessed Dec 25, 2016). We identified 19 out of these 29 
actionable variants in our cohort, with 161 patients (65.7%) harboring at least one CPIC 
level 1A/1B homozygous variant (Figure S8, Appendix E). We observed high read 
coverage in regions comprising CPIC Level 1A/1B variants as well as rare or novel SNVs 
with a CADD score >20 (Figure S10, Appendix E), illustrating the capacity of our gene 
panel for comprehensive genetic profiling of pharmacogenes with clinical relevance. 
 
5.3.5 SNV discovery in apixaban AF cohort 
We applied our panel in a small group of AF patients with either a high (n = 6) or normal 
(n = 6) apixaban plasma concentration phenotype (patient characteristics in Table 5-3). 
Exonic and clinically relevant SNVs identified within the candidate genes selected for 
exploratory analysis among the high and normal apixaban concentration groups is shown 
Table 5-4. With the exception of a single variant within the NR1I2 gene (rs149041795) 
belonging to an individual from the normal group, the remainder of nonsynonmous SNVs 
that were found in ABCB1, ABCG2, CYP3A4, and CYP3A5 (no exonic variants were found 
in NR1H4) were common and not predicted to be deleterious according to in silico 
functional assessment tools. ABCG2 c.421C>A and CYP3A5*1 variants, have been 
reported to be associated with higher and lower apixaban plasma concentrations in Japanese 
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AF patients, respectively (16, 17). We observed a slightly greater frequency of the ABCG2 
c.421A allele in our high group compared to the normal group, and overall only one 
individual in our normal group was a carrier of the CYP3A5*1 allele. We also identified 
individuals that were carriers for common functionally established variants found within 
our selected candidate genes. Two individuals within the high group were carriers of the 
POR*28 variant. While within the normal group, one individual had a copy of the 
CYP3A4*22 variant, and another individual had copy of the FXR/ NR1H4 c.-1 G>T variant. 
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Table 5-3. Characteristics of apixaban-treated atrial fibrillation patients selected for 
sequencing. 
 
Characteristic  Apixaban concentration 
  Normal High 
Subjects, n 6 6 
Age, median (IQR) 68 (65-77) 70 (64-77) 
Sex, Male (%) 100.0% 33.3% 
Weight, kg, median (IQR) 106.6 (74.9-133.6) 95.0 (79.6-114.4) 
Apixaban Dose 
  
5 mg twice daily, (%) 5 (100.0) 5 (83.3) 
2.5 mg twice daily, (%) 0 (0) 1 (16.6) 
Hours post dose, mean (min-max) 7.0 (6.3-7.8) 5.4 (3.2-8.9) 
Apixaban plasma concentration   
ng/ml, median (IQR) 145.1 (120.2-155.8) 404.1 (260.8-445.3) 
ng/ml/mg, median (IQR) 29.0 (24.0-31.2) 87.0 (70.3-93.0) 
Serum Creatinine, µmol/L, median (IQR) 95.0 (70.0-105.0) 63.5 (51.8-82.0) 
Creatinine Clearance, mL/min, median (IQR) 114.2 (78.16-183.2) 114.0 (95.8-132.3) 
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Table 5-4. Single nucleotide variants identified within high versus normal apixaban concentration groups. 
Gene  Allele Polymorphism Type of SNV dbSNP137 No. of 
algorithms 
predicting 
as 
damaginga 
1000G 
(Euro) 
ExAC High group 
‡ 
Normal 
group ‡ 
AF AF AF  AF 
  
(n=6) (n=6) 
ABCB1 
 
c.2677 G>T nonsynonymous rs2032582 0/3 0.57 0.54 0.50 0.67 
ABCB1 
 
c.2677 G>A nonsynonymous rs2032582 0/3 NF 0.04 0.08 0.08 
ABCB1 
 
c.61 A>G nonsynonymous rs9282564 0/3 0.09 0.08 0.08 NF 
ABCB1 
 
c.3435 T>C synonymous rs1045642  (18, 19)† 0.47 0.5 0.50 0.58 
ABCB1 
 
c.2359 C>A synonymous rs200903110 - NF 1.65E-05 0.08 NF 
ABCB1 
 
c.1236 T>C synonymous rs1128503 - 0.57 0.54 0.67 0.67 
ABCB1 
 
c.210 A>G synonymous rs2214102 - 0.9 0.94 0.92 0.83 
ABCG2 
 
c.421 C>A nonsynonymous rs2231142 (20, 21)† 0.1 0.12 0.25 0.17 
CYP3A4 
 
c.1242 C>G synonymous NF - NF 9.06E-05 0.08 NF 
CYP3A4 *22 c.522-191 C>T intronic rs35599367 (22)† 0.05 NF NF 0.08 
CYP3A5 
 
c.423 A>G loss of stop 
codon 
rs6977165 - 0.03 0.05 NF 0.08 
CYP3A5 *3 g.6986 A>G splice rs776746 (23)† 0.95 NF 1.00 0.92 
NR1H4 
 
c.-1 G>T 5'UTR rs56163822 (24)† 0.02 0.08 NF 0.08 
NR1I2 
 
c.1135 T>G nonsynonymous rs149041795 1/3 NF 2.00E-04 NF 0.08 
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NR1I2 
 
c.879 T>C synonymous rs4058490 - 1 1 1.00 1.00 
POR *28 c.1508 C>T nonsynonymous rs1057868 (25) † 0.3 0.36 0.25 NF 
POR 
 
c.15 A>G synonymous rs10262966 - 0.01 0.07 NF 0.08 
POR 
 
c.387 A>G synonymous rs1135612 - 0.26 0.27 0.50 0.17 
POR 
 
c.1455 T>C synonymous rs2228104 - 0.97 0.92 1.00 0.92 
POR 
 
c.1716 G>A synonymous rs1057870 - 0.33 0.38 0.17 0.67 
‡ Colours range represents allele frequencies: (◻) not found or 0%, to 100% (◼) 
Abbreviations: AF, allele frequency; dbSNP 137, Single Nucleotide Polymorphism database build 137; ExAC, Exome Aggregation 
Consortium version 0.3; 1000G EUR, 1000 Genomes Project European dataset; NF, not found in dbSNP 137, 1000G EUR, ExAC database, 
respectively, apixban group. (†) References for known functionally established SNVs in bracklets. (ª) Patient-specific SNV defined as 
damaging if scaled CADD score >20 (11), a SIFT score <0.05 (12), or a PolyPhen-2 score >0.85 (13) 
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5.4 Discussion 
The principal findings of this study comprise: 1) the development of a 
comprehensive targeted NGS gene panel for most clinically important 
pharmacogenetic loci; 2) demonstrating the utility of this panel to simultaneously 
detect common and rare variants with minimal to no artefacts resulting from difficult 
to sequence regions; 3) demonstrating that PGxSeq performs at least as well as, and 
usually better than, current standard pharmacogenetic assays; 4) our exploratory 
analysis did not reveal likely deleterious SNV(s) within the selected candidate genes 
in the apixaban-treated AF subjects that were sequenced, that may potentially 
explain their observed elevated apixaban plasma concentration. Moreover, our 
results support the high prevalence of rare or novel variants of potential functional 
relevance within pharmacogenes. 
Compared to traditional genotyping or sequencing strategies, the applied 
targeted exome sequencing strategy enabled the comprehensive discovery of novel 
rare SNVs as well as accurate genotyping for common, previously established 
functional variation across exonic and intergenic regions in clinically important 
pharmacogenes with fast and adequate performance. Available bioinformatics tools 
further allowed customized utilization of sequencing data at a small or large scale, 
i.e. the assessment of individual genotypes and genes of interest or a more exhaustive 
pharmacogenetic analysis. Our target sequence included 29 clinically actionable 
variants with recommendations to adjust dose or for alternative therapies. Nearly all 
patients (97%) harboured one or more CPIC Level 1A/1B variant(s) confirming 
recent findings from the eMerge-PGx study comprising extensive sequencing data 
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from 5000 patients for 82 pharmacogenes (26). The multitude of other, newly 
discovered candidate variants among CPIC genes in this study highlights the need 
for comprehensive sequencing approaches to determine the likely more complex 
genotype of a patient, while high-throughput experimental strategies are warranted 
to screen and confirm effects of previously unreported genetic variation on protein 
activity. 
A significant number of pharmacogenetic variants detected in our total cohort 
was either rare or novel (60%), and more than half (56%) resulted in amino acid 
changes, supporting previous observations in larger datasets (1, 26-28). While the 
proportion of SNVs with predicted effects on protein function differed among 
applied in silico tools, differences in scoring have been previously observed and are 
not surprising given the way these algorithms were derived (29). SIFT leverages the 
evolutionary conservation of amino acids (12), PolyPhen-2 uses pathogenicity 
information (13), while CADD is the most recent algorithm integrating conservation 
metrics, regulatory information, and protein-level effect among others (11). A recent 
study suggests that the in silico algorithms used here predict altered enzymatic or 
transporter function with about 80% accuracy compared to in vitro assessment (29). 
Among the possibly deleterious variants identified, rare or novel SNVs were more 
likely to have functional effects than common or low frequency variants (Figure S6, 
Appendix E), with 43.1 – 53.5 % of rare or novel SNV predicted to be deleterious 
according to in silico algorithms. These findings are similar to a recent report 
evaluating NGS data from thousands of individuals in 146 pharmacogenes, where 
30% to 40% of rare variation was predicted to be functional (1). Moreover, we found 
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that 94% of patients (231 of 246) carried at least one deleterious allele (CADD score 
>20) in 12 CYP genes with key roles in drug metabolism (27, 30); these potentially 
clinically relevant findings need to be followed up. 
In this study, accurate variant and genotype calls were obtained in 
pharmacogenes previously reported to be structurally problematic due to sequence 
similarities but also due to highly variable or repetitive regions (29, 31-34). NGS-
derived genotypes were concordant with TaqMan results for all the common and/or 
clinically relevant SNP that were tested. In addition, retrospective Sanger sequencing 
confirmed 5 of the 5 rare variants identified by NGS in a subset of relevant genes.  
Genetic profiling using any short-fragment sequencing platform is a widely 
recognized challenge for NGS of pharmacogenes (31, 35), and requires sufficient 
representation of mapped sequenced reads in the region of interest to ensure 
accuracy. As expected, many members of the CYP, SULT and UGT gene families 
were reported as harbouring 250-bp sequence fragments that map to more than one 
place in the genome due to their sequence similarity, with regions that are up to 100% 
identical (i.e. pseudogenes) predicted of being the most problematic (36). An 
estimated 1.8% of our 422kb target sequence (69 exons in 19 genes) was found to 
be susceptible to potential mismapping. Although our hybridization-based 
enrichment strategy achieved a mean read coverage above 80x for most genes (98 of 
100), the results also indicate that the mean value alone may not always correctly 
indicate sufficiently even read coverage across the targeted coding region. 
Specifically, for CES1 a mean DOC ≥ 80 × was observed, however 30.2% of its 
targeted bases (Exon 12 - 14) showed a DOC <30 × indicating areas prone to higher 
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error rates (Figure 5-2, Figure S3 Appendix E); a 95 - 100% sequence similarity 
has been previously reported for CES1 exons 12 - 14 (36). Accordingly, high 
homology regions may benefit from longer capture probes for hybridization-based 
target enrichment to ensure appropriate capture and/or sequence read mapping. 
Moreover, DOC for GSTM1 and GSTT1 were the lowest among all genes of our 
panel. A previous report in a Korean population sample showed individuals with 
GST gene deletion (GST*0) lacked coverage when assessed with NGS, while the 
number of gene copies correlated the mean number of sequencing reads (29). 
Deletions of GSTs are also prevalent among Europeans (MAF ~ 0.5 (37)), and we 
noted 52% and 21% of our study group had near zero coverage for GSTM1 and 
GSTT1, respectively, likely representing GST*0 carrier status (Figure S9, Appendix 
E). While NGS is thought to be best suited for the detection of SNV, our findings 
and most recent reports suggest that a read-depth based approach may be also used 
for the identification of CNV as demonstrated for GSTs (29), the LDL receptor 
(LDLR) (38) and various genes underlying retinal dystrophies (39) using gene 
panels, as well as CYP2D6 utilizing whole-genome sequencing data (33). Our 
findings highlight the need for monitoring targeted regions for low sequence 
coverage, absent data or ambiguous calls to reduce false negative or positive findings 
by defining test panel limitations in agreement with current clinical laboratory 
standards for NGS (40).  
Utilizing existing knowledge of apixaban’s metabolism and disposition, we took 
a candidate gene approach to explore new, previously not recognized single 
nucleotide variations that potentially correlate with apixaban concentration 
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phenotype in a small subgroup of AF patients. While our sample size is too small to 
draw any statistical inferences, we compared the variants identified between subjects 
with high and normal concentration phenotypes using descriptive statistics. We did 
not find rare or patient-specific deleterious SNV(s) within the seven candidate genes 
in our subjects belonging to the high group that may potentially explain their 
observed elevated apixaban plasma concentration. Furthermore, the distribution of 
common clinically relevant SNVs identified between the high versus normal 
concentration group were not always conceptually consistent with the known 
functional effect of each variant.  For instance, the POR*28 variant, which has been 
reported to be associated with increased CYP3A activity (25), was observed only in 
the high group (1 heterozygous, 1 homozygous). Theoretically, this variant would 
be protective against higher apixaban plasma concentration. On the other hand, we 
observed a higher frequency of the reduced function variant ABCG2 c.421 C>A 
within the high concentration group compared to the normal group. This observation 
is consistent with the high concentration phenotype, the ABCG2 gene codes for the 
transporter, breast cancer resistance protein (BCRP), which plays a role in limiting 
the absorption of apixaban in the gut (41). It is also worth noting that, even though 
the in silico prediction tools that were used focus on the impact of nonsynonymous 
SNVs, we cannot rule out the influence of synonymous or non-coding variants 
(intronic, 5’ or 3’ untranslated regions). A classic example of this is the synonymous 
ABCB1 c.3435C>T variant which has been implicated in altering the 
pharmacokinetics and pharmacodynamics of a number of drugs (19, 42).  
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 While we show the potential application of targeted exome sequencing as a 
comprehensive pharmacogenetic profiling tool, there are some limitations. 
Validation of concordance was limited to variants in 41 loci in 21 genes in our 
relatively small, mostly Caucasian sample, in contrast to previously reported multi-
center studies that assessed hundreds of SNVs in larger populations (29, 32) 
including commercially available DNA control samples (29, 40). At present, despite 
high concordance rates for common CYP2D6 and CYP2C9 variants, we cannot 
exclude false-positive variant calls. We intend to further evaluate our panel 
considering intronic SNVs and CNVs for CYP2D6 in a larger, previously 
characterized patient sample. Despite the small sample size, the herein observed 
variation compared well to findings from larger data sets. 
Next-generation sequencing platforms are starting to impact upon many clinical 
fields, especially cancer and pediatrics. Bringing these technologies to clinical 
pharmacogenetics represents a timely and logical convergence, especially given the 
history of applied genetic concepts and molecular methods within the discipline.  
Through comprehensive validation of performance and accuracy, results from our 
study and others demonstrate the utility of targeted exome sequencing panels as 
sensitive and reliable sequencing platforms for pharmacogenes (29, 32). But despite 
the relative ease of the sequencing process, the time and effort required for post-
sequencing computational and bioinformatics data analyses are significant due to the 
technical and interpretive complexity of NGS and the biology of some 
pharmacogenetic gene targets. Moreover, as new variants are discovered using these 
high-throughput detection methods, the need for standards in attributing 
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pathogenicity together with development of tools for high-throughput functional 
assessment and clinical validation are required before implementing findings to aid 
therapeutic decision-making. 
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6.1 Summary and Discussion 
6.1.1 Chapter Three 
Factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, represent a new class of oral 
anticoagulants that are widely prescribed as an alternative to warfarin therapy for 
stroke prevention in patients with atrial fibrillation (AF). An important advantage of 
these drugs is that routine monitoring of anticoagulation response is not necessary. 
Nevertheless, because of their mechanism of action, FXaI pharmacological effect 
can be inferred based on the observed plasma drug concentration, yet there is a 
paucity of data relating to variation in FXaI concentration among patients taking 
these drugs in the post-market clinical setting. Therefore, the aim of Chapter Three 
was to measure the extent of interpatient variation in the circulating FXaI plasma 
concentrations of 243 atrial fibrillation patients prescribed rivaroxaban and apixaban 
within a routine clinical care setting, and we hypothesized that this variation was 
greater than that observed in clinical trials. In our routine-care setting rivaroxaban 
and apixaban plasma concentrations tended to be more variable than those observed 
in clinical trials, with approximately 12% of patients receiving rivaroxaban and 13% 
of patients receiving apixaban exceeding the 95th percentile for the predicted 
maximum plasma concentration observed in clinical trials. These results supported 
our hypothesis, and accordingly we set out to identify additional clinical and 
molecular determinants that more fully predict patients at risk for excessively high 
or low FXaI concentration. 
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6.1.2 Chapter Four 
Renal function, age, sex, weight, as well as carrier status for functional genetic 
polymorphisms within genes that code for proteins involved in the transport (ATP 
binding cassette [ABC] G2 gene) and metabolism (cytochrome P450 [CYP] 3A5 
gene) of apixaban have been demonstrated to impact the elimination of the drug in 
humans as indicated by altered apixaban pharmacokinetics, and ultimately drug 
exposure (1-4). Furthermore, as part of its metabolism, apixaban is primarily 
oxidized by CYP3A enzymes (5, 6). However, the relationship between apixaban 
blood concentrations and endogenous markers of CYP3A activity, as a predictor for 
interindividual variability of apixaban exposure, has not been determined. 
Accordingly, the aim of this chapter was to examine 4β-hydroxycholesterol (4β-
OHC) (as a marker for apixaban metabolism) along with the factors that are known 
to impact apixaban exposure such as renal function, age, sex, weight, and common 
genetic variation, in order to better explain the variation in concentration observed 
within our apixaban-treated cohort. We hypothesized that 4β-OHC concentration 
with clinical and genetic variables would better explain the variation in FXaI 
concentration compared to clinical and genetic factors alone. We found a weak but 
statistically significant correlation between plasma concentrations of apixaban and 
4β-OHC, with higher 4β-OHC concentrations (higher CYP3A4 activity) associated 
with lower apixaban concentrations. Moreover, multivariable linear regression 
analysis demonstrated that 4β-OHC concentration was an independent predictor of 
apixaban concentration in our cohort along with age, female sex, serum creatinine, 
and amiodarone use. Weight, diltiazem use, as well as CYP3A4*22, CYP3A5*3, 
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ABCB1 c.3435C>T, or ABCG2 c.421C>A carrier status were not significant 
predictors of apixaban plasma concentration in our cohort. Although our findings 
supported our hypothesis, we accounted for only 27.9% of the interindividual 
variability in FXaI plasma concentration observed in our apixaban-treated AF cohort 
(n = 119), leaving the majority of the variation unaccounted for. 
 
6.1.3 Chapter Five 
Clinical variables, common genetic variation, and 4β-hydroxycholesterol 
concentration accounted for 31% of the interindividual variability in FXaI plasma 
concentration observed in our apixaban-treated AF cohort (n = 119), leaving the 
majority of the variation unaccounted for. Therefore, we hypothesized that part of 
this unexplained variation was the result of certain individuals harbouring rare or 
patient-specific functional single nucleotide variants (SNV) within candidate genes 
encoding drug transporters and enzymes relevant to apixaban’s disposition. Recent 
large-scale whole genome or exome sequencing studies have revealed that humans 
harbor a large number of rare, and/or potentially deleterious variants in genes 
relevant to drug disposition and response (7, 8). Targeted next-generation 
sequencing (NGS) represents a new time- and cost-effective technology for detecting 
common and rare genetic variation. In Chapter Five, we aimed to develop a targeted 
sequencing approach to detect common and rare genetic variation in pharmacogenes 
pertinent to drug disposition and response. We subsequently, applied this method for 
single nucleotide variant discovery in a subgroup of apixaban-treated AF patients 
with aberrantly high apixaban plasma concentrations compared to controls. Overall. 
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we were able to generate a sufficient depth-of-coverage (DOC) >30x for 97.4% of 
the target sequence, and for a select number of SNVs (32 common and 5 rare or 
novel) we confirmed concordance between genotypes determined by NGS versus 
TaqMan genotyping or Sanger sequencing. More specifically, our exploratory 
analysis did not reveal likely deleterious SNV(s) within the selected candidate genes 
in the apixaban-treated AF subjects that were sequenced, which may potentially 
explain their observed elevated apixaban plasma concentration. Although this did 
not support our hypothesis, at this point we cannot rule out the influence of 
synonymous or non-coding variants (located in intronic, 5 or 3 prime untranslated 
regions), as well as structural variants (copy number variations or large insertion and 
deletions), as these variations could also have influence over gene expression, and 
in turn the exposure of apixaban in these individuals. We were also limited by a small 
sample size, sequencing a larger cohort would have allowed us to test for a difference 
in the burden of SNVs within these candidate genes between our high and control 
group. 
 
6.2 Therapeutic implications 
Since their approval, the use of direct-acting oral anticoagulants (DOACs), such as 
apixaban and rivaroxban, for stroke prevention in patients with AF has rapidly 
increased (9, 10), owing to their ease of prescribing and management. While warfarin 
prescribing is complicated by routine INR testing and high interpatient variability in 
the required therapeutic dosage (20-fold), DOACs offer fixed dosing (up to 2-fold) 
without the need for routine monitoring. Although DOACs appeared to have a 
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favourable risk-benefit profile in clinical trials compared to warfarin (11), major 
bleeding is still a complication associated with DOAC use. Moreover, the patient 
population that take DOACs in the post-market setting may vary greatly with their 
co-morbidities and extensive co-medications from those within clinical trials. As 
prescribing trends in clinical practice continue to favour the use of DOACs, the 
number of bleeding events associated with them is likely to increase as well. 
Identifying factors that increase the DOAC-associated bleeding risk in patients 
before prescribing these drugs can help to mitigate adverse drug events. Aside from 
non-DOAC related factors that increase bleeding risk such as advanced age, 
pharmacodynamic interactions from co-medications, and medical conditions or 
procedures with a pre-existing risk for hemorrhage; prolonged elevation of DOAC 
plasma concentrations will exacerbate the risk of bleeding associated with the use of 
these medications (12-15).  
As observed in Chapter Three, when dosing according to clinical guidelines, the 
measured FXaI plasma concentrations for a subgroup of AF patients taking apixaban 
and rivaroxaban within a routine care setting will likely fall in the extremes of FXaI 
drug exposure. Although, our study was not designed to identify an association 
between FXaI concentration and bleeding or stroke events, this relationship has been 
described in the product monograph of apixaban (12), rivaroxaban (15), and more 
recently published for edoxaban (a novel FXaI inhibitor) (16). However, without an 
established threshold for efficacy (thrombosis) or safety (bleeding), such as the one 
established for warfarin with INR, making dose adjustments or constructing dose 
algorithms based on observed FXaI concentrations will remain to be clinically 
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challenging. Ultimately, our findings provide support for a need to establish a 
therapeutic range of FXaI plasma concentrations for which the risk of bleeding and 
stroke are at the lowest.  On the other hand, physicians can currently use FXaI plasma 
concentration as a means to ensure patient compliance, especially among those 
patients experiencing stroke or transient ischemic attacks while prescribed 
rivaroxaban and apixaban. 
In Chapter Four, we attempted to characterize the inter-individual variability in 
the FXaI plasma concentrations observed in our apixaban-treated AF cohort from 
Chapter Three. We found that the majority of the explainable variation in apixaban 
concentration was accounted for by age and renal function which are currently 
assessed as part of apixaban dose selection. In addition to this, our results 
demonstrated that measuring endogenous biomarkers of CYP3A4 activity such as 
4β-hydroxycholesterol may help determine whether an unexpectedly low apixaban 
plasma concentration is the result of high CYP3A4 activity. This can provide 
physicians with an additional layer of evidence to support increasing apixaban 
dosage or a change in medication to one that is independent of CYP3A4 metabolism. 
Concomitant use of amiodarone was associated with higher apixaban plasma 
concentration in our AF cohort. Patients who experience bleeding while taking 
amiodarone with apixaban, may benefit from therapeutic drug monitoring as a 
method for dose adjustment, especially if they have elevated apixaban 
concentrations.  
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6.3 Future direction 
Future prospective studies involving AF patients within routine care that focus on 
rivaroxaban and apixaban exposure in relation to clinically relevant outcomes (major 
bleeding, stroke, death) are needed to determine the FXaI concentration thresholds 
for safety (bleeding) and efficacy (stroke). Not only will this help elucidate the true 
clinical significance of the observed variation in FXaI plasma concentration that was 
found in our studies, but it will also accelerate the field of research involved in 
characterizing FXaI interpatient variation.  
The study we carried out in Chapter three was observational, involving 
patients who were recruited during their routine care visits. As such, we were limited 
in our ability to account for the effect of adherence as well as inaccurate self-
reporting of time of last-dose on the drug concentration. Therefore, it remains 
possible that unreported missed doses or drug intake without food (rivaroxaban only) 
may explain some of the inter-patient variability especially in patients with very low 
plasma concentrations. Prospective studies, that ensure both patient adherence to 
dosing and sampling of blood to obtain either trough FXaI plasma concentrations or 
an area-underneath-the-curve, would likely reduce the proportion of unexplained 
variation. 
Recent work carried out in a Japanese AF population have reported the 
ABCG2 421A/A and CYP3A5*1/*1 genotype to be associated with higher and lower 
trough apixaban concentrations, respectively (4, 17). While we did not observe an 
association between these functional polymorphisms and variability in apixaban 
plasma concentration, this may in part be due to the fact that there weren’t many 
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variant carriers in our cohort. Further studies in larger AF cohorts including more 
variant carriers from different ancestries will help confirm the effect of these 
polymorphisms on apixaban plasma concentration, while in vitro and animal studies 
characterizing the molecular mechanism behind the altered plasma concentration 
(i.e., decreased absorption and/or reduced excretion) would strengthen Ueshima et 
al., observations in human. For instance, in vitro experiments examining the 
difference in the vectorial transport of apixaban within human intestinal and kidney 
cell models expressing wildtype ABCG2 (breast cancer resistance protein, BCRP) 
or the c.421C>A variant. 
Through developing our targeted NGS panel (Chapter Five) we discovered the 
majority of individuals that were sequenced had some degree of burden in terms of 
deleterious SNVs across their pharmacogenes. These variants ranged from clinically 
actionable SNVs, with a strong evidence for influencing drug efficacy/response, to 
newly discovered candidate SNVs that were predicted to be deleterious according to 
in silico functional assessment tools. The multitude of variants detected in each 
individual highlights the need for comprehensive sequencing approaches to 
determine the likely more complex genotype of a patient. But despite the relative 
ease of the sequencing process, the time and effort required for post-sequencing 
computational and bioinformatics data analyses are significant; complicated by the 
technical and interpretive complexity of NGS and the biology of some 
pharmacogenes. One of the areas that will benefit from developing more integrated 
software for post-sequencing data extraction is the identification of copy number 
variations from NGS data, including partial gene insertions and deletions – 
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eventually becoming a growing area of research as it pertains to genotyping (18-20).  
Additionally, the field of pharmacogenetics will likely benefit from in silico 
prediction tools that tailor the impact of an amino acid change in terms of its 
influence on drug-protein substrate specificity for a drug of question – perhaps by 
incorporating knowledge of the regio-specific interactions between drug substrates 
and the relevant proteins involved in their disposition pathway. This will assist in 
filtering worthwhile candidate variants for investigation in those FXaI-treated AF 
subjects who demonstrate unexpectedly high or low drug plasma concentrations. 
Ultimately, as variants are discovered using these high-throughput detection 
methods, the need for standards in attributing pathogenicity together with 
development of tools for high-throughput functional assessment and clinical 
validation are required before implementing findings to aid therapeutic decision-
making. 
 
6.4 Conclusion 
Today, FXaIs are prescribed at fixed doses without the need to assess the degree of 
anticoagulation. As prescribing trends in clinical practice continue to favour the use 
of FXaIs for preventing cardioembolic stroke in patients with atrial fibrillation, the 
number of adverse events associated with these drugs is likely to increase as well. 
The identification of factors that drive variation in FXaI exposure and response will 
provide the basis for a safe, yet efficacious approach to dose selection. The studies 
presented within this thesis provide insight into the factors that drive variation in 
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FXaI concentration, and may serve as a framework for future investigations 
regarding personalizing FXaI anticoagulation therapy.  
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Appendix C 
 
Multiple linear regression coefficients for apixaban plasma concentration in atrial 
fibrillation patients (n = 119). 
Predictor variable B 95% CI P-value 
Dose  0.109 0.073, 0.146 <0.001 
Hours post dose -0.016 -0.035, 0.002 0.086 
Age, years 0.008 0.004, 0.012 <0.001 
Sex, Female 0.069 -0.006, 0.144 0.069 
Weight, kg <0.001 -0.002, 0.002 0.985 
Serum creatinine,  µmol/L 0.002 0.001, 0.003 <0.001 
ABCB1 c.3435C>T , per allele 0.001 -0.049, 0.051 0.972 
ABCG2 c.421C>A, 1 or 2 allele 0.063 -0.018, 0.144 0.125 
CYP3A4*22, 1 or 2 allele 0.027 -0.069, 0.124 0.574 
CYP3A5*3, 1 or 2 allele 0.002 -0.111, 0.116 0.971 
Amiodarone use 0.128 0.027, 0.230 0.014 
Diltiazem use 0.015 -0.080, 0.110 0.756 
Adjusted R squared 0.235. 
 
 
 162 
Appendix D 
 
Detailed methods 
Sample collection 
 Genomic DNA (gDNA) was obtained from venous blood samples of 245 
Caucasian subjects following written informed consent. We initially evaluated 
sequencing performance and accuracy of variant detection in the first 48 subjects − 
this was our validation cohort. Following this, all 245 subjects that were sequenced 
were used to evaluate genetic variation in terms of population allele frequencies and 
predicted functional effect. Then we carried out candidate gene SNV discovery in a 
subgroup of 12 AF patients with a known apixaban drug concentration phenotype. 
This study was approved by the Research Ethics Board of Western University, 
London, Canada. 
 
Gene selection, capture probe design and enrichment method 
 We used the Nextera Rapid Capture Custom Enrichment Kit (Illumina, San 
Diego, CA) for the enrichment of genomic regions of 100 genes encoding major 
cytochrome P450 (CYP) enzymes, phase II conjugation enzymes, drug transporters 
of the solute carrier (SLC) and ATP binding cassette (ABC) families as well as 
regulatory proteins of relevance to variability in drug ADME (absorption, 
distribution, metabolism, excretion) and response. In addition, regions 
encompassing 14 known functional promoter or intronic SNVs were included (Table 
1).  
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Table S1. Promoter and intronic SNVs included in probe design. 
 Gene Allele dbSNP137 Positionᵃ 
Promoter 
regions 
CYP1A2 *1C rs2069514 Chr15:75038220 
CYP2C19 *17 rs12248560 Chr10:96521657 
UGT1A1 *28 rs8175347 Chr2:234668881: 
234668882 
UGT1A1 *60 rs4124874 Chr2:233757013 
VDR 
 
rs11568820 Chr12:47908762 
VDR 
 
rs4516035 Chr12:47906043 
VKORC1 
 
rs9923231 Chr16:31096368 
NR1H4 
 
rs56163822 Chr12:100493323 
Intronic 
regions 
CYP1A2 *1F rs762551 Chr15:74749576 
CYP3A4  *22 rs35599367 Chr7:99768693 
VKORC1 
 
rs9934438 Chr16:31093557 
CYP3A5 *3 rs776746 Chr7:99672916 
CYP2D6 *41 rs28371725 Chr22:42127803 
NR1I2 
 
rs2276707 Chr3:119815306 
(ᵃ) Chromosome position based on the GRCh37 assembly    
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A total of 10,207 capture probes (80 bp) were custom-designed using the 
Illumina Design Studio (Illumina, San Diego, CA) comprising 722 kilobases (kb) of 
sequence per sample (Genomic coordinates can be found in Table S1, Supplemental 
Digital Content 1). Exons of all coding isoforms were targeted for selected genes 
including 300-bp intronic (flanking each exon) and 250 bp of 5' and 3' untranslated 
regions (UTR). Chromosomal coordinates were obtained from University of 
California Santa Cruz (UCSC) genome browser using the GRCh37/hg19 human 
genome assembly. DNA library preparation and subsequent target-capture 
sequencing was conducted at the London Regional Genomics Center, London, 
Ontario, as previously described (1). Briefly, DNA samples were processed in runs 
in batches of 12 or 24 samples. After serial dilutions, DNA was adjusted to a final 
concentration of 5.0 ± 1 ng/µl using the Qubit DNA kit (Invitrogen, Eugene, OR). 
DNA was enzymatically fragmented, polymerase chain reaction (PCR)-amplified 
with individual sample barcodes, equimolar pooled, hybridized to the biotinylated 
capture probes, pooled using streptavidin beads, and PCR-amplified again to select 
the final target sequence. Resulting libraries were quantified, and loaded on to a 
standard flow-cell on the Illumina MiSeq Sequencer (Illumina, San Diego, CA) 
using 2 x 300 bp or 2 x 150 bp paired-end chemistry. 
 
Base calling, sequence alignment and variant detection 
Prior to the alignment of reads to the reference genome, sequencing performance 
metrics were assessed. For each run, cluster density (1000/mm2), total number of 
reads passing instrument filters and per base quality score (also Phred score, Q; 
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describes the probability of a sequencing error as a measure of base call accuracy) 
was obtained. Paired-end sequenced reads were separated according to sample-
specific barcodes and sequencing data downloaded as FASTQ files that were further 
assessed with the quality control tool, FastQC (2), including base quality across 
reads, per sequence GC content, sequence length distribution and duplication level 
(3).  
Alignment of sequencing reads and variant calling were performed using the 
CLC Bio Genomics Workbench 7.0 (CLC Bio, Aarhus, Denmark) through a custom-
automated workflow. FASTQ files were imported and mapped to the reference 
human genome (GRCh37/hg19 build). Using default algorithms (i.e. Local 
Realignment and Remove Duplicate Mapped Reads), initial read mapping was 
further optimized around insertion-deletion mutations (indels) and PCR duplicates 
removed. To further ensure accuracy of variant and genotype calling, quality-based 
variant detection tools were employed with the following parameters: diploid 
organism, probability of non-reference allele ≥ 95% (versus sequencing error), ≥ 10-
fold coverage (10 x), ≥ 30% read frequency, and ≥ 30 per base quality score at the 
variant location. Resulting sequence variation reports were exported in variant call 
format (VCF) for downstream annotation.  
Coverage (also read depth) or depth-of-coverage (DOC) was defined as the 
number of reads mapped to a genomic position following alignment of sequenced 
reads and removal of duplicate reads. Reads that were non-specific matches (mapped 
to more than one location of hg19 reference genome) or missing the paired read were 
excluded from this calculation. For every subject, a Coverage Summary Report 
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along with a base-by-base Coverage Table were exported. Coverage analysis was 
restricted to coding regions, including 10 bp before and after each exon, and 250 bp 
of 3' and 5'UTR. We assessed inter-subject and intra-subject variability of DOC 
across target sequence by sequencing cluster (n = 12 or 24), and the mean (SD) for 
each gene. As an additional indicator of low coverage regions within a gene we 
expressed DOC as the percentage of targeted bases having mean DOC < 30 ×. 
 
Variant annotation and in silico functional assessment 
Functional annotation of SNVs was carried out using ANNOVAR (4) through in 
silico prediction algorithms such as Combined Annotation Dependent Depletion 
(CADD) (5), Sorting Intolerant from Tolerant (SIFT) (6), and PolyPhen-2 (7), and 
variant frequency among different populations were determined utilizing large 
genomic databases (RefSeq, dbSNP137, 1000 Genomes, Exome Aggregation 
Consortium [ExAC]; obtained July 8, 2015). SNVs with a CADD Phred score 
(scaled) greater than 20 (5), a SIFT score of less than 0.05 (6), or a PolyPhen-2 score 
of greater than 0.85 (7) were considered as potentially functional variants (altering 
protein function), and herein defined as " deleterious". Variants were classified as 1) 
non-synonymous (coding variants resulting in amino acid change), 2) synonymous 
(coding variants without amino acid changes), 3) frameshift deletion or insertion (in-
del), 4) splicing (3 nucleotides within an intron-exon boundary), 5) stop gain or loss, 
or 6) functional intronic or promoter variants. Coding variants were further grouped 
by MAF reported in the ExAC database as common (MAF ≥ 5%), low frequency 
(1% ≤ MAF > 5%), or the combined category of rare (MAF < 1%) and novel (absent 
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from ExAC and dbSNP build 137 databases). In silico functional assessment was 
restricted to protein-coding genetic variation and gain or loss of a stop codon.  
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Concordance assessment 
To assess concordance of NGS results, orthogonal genotyping was performed using 
TaqMan allelic discrimination for 32 common functionally validated or clinically 
relevant SNVs. Rare NGS variants were confirmed retrospectively by Sanger 
sequencing within 7 pharmacogenes. Polymerase chain reaction conditions and 
primers for Sanger sequencing and TaqMan assay IDs are listed in Table 2, and 
Table 3 respectively. 
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Table S2. Polymerase chain reaction conditions and primers used for Sanger sequencing of rare NGS variants. 
Abbreviations: dbSNP137, Single Nucleotide Polymorphism database build 137; PCR, polymerase chain reaction; FOR, 
forward primer; REV, reverse primer. 
(ᵃ) Chromosome position based on the GRCh37 assembly        
(ᵇ) CYP2D6 PCR method included a pre-amplification of the whole gene using long template PCR using the forward 
(GGTAAGGGCCTGGAGCAGGAA) and reverse primer (GCCTCAACGTACCCCTGTCTC) described by Stüven et 
al, (12), followed by purification and subsequent sanger sequencing using the primers listed above. 
Gene dbSNP137/Positionᵃ  PCR Target Primer set Product  Ref. 
    Exon RefSeq  (5' to 3') Size 
(bp) 
  
ABCB1 rs55852620 (24/26) NM_000927 FOR 
REV 
 
GAGAATTAATCTATGTGATTATGG-
GTATTTAACATCTCATACAGTCAGAG 
263 (8) 
CYP2D6ᵇ rs5030867 (6/9) NM_000106 FOR 
REV 
 
GCTAACTGAGCACA-
CCGGCCCTGACACTCCTTCT 
577 (9) 
SLCO1B1 Chr12:21350002 (8/15) NM_006446 FOR 
REV 
 
AATCTTACATGACTTACGTTCAC-
CCACTTGGAATACAGTATTTAG 
242 (10) 
 
SLCO1B1 Chr12:21355448 (10/15) NM_006446 FOR 
REV 
 
TCTGCTTTCACTTTACTTCTTCC-
GAATAAGGAGAGGAAAGTAAAAAC 
195 (10) 
SLCO1B3 Chr12:21011433 (3/14) NM_001009562 FOR 
REV 
 
GGGCATTCAGTTCTACTAGA- 
TAATAAATGGCTCAGAGCTG 
233 (11) 
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Table S3. TaqMan assay ID for the common functionally validated clinically 
relevant SNVs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Gene dbSNP TaqMan Assay ID 
ABCB1 rs1045642 C___7586657_20 
ABCC2 rs2273697 C__22272980_20 
ABCG2 rs2231142 C__15854163_70 
ABCG2 rs2231137 Custom design 
(13) 
CYP2B6 rs3211371 C__30634242_40 
CYP2B6 rs3745274 C___7817765_60 
CYP2C19 rs12248560 C____469857_10 
CYP2C19 rs4244285 C__25986767_70 
CYP2C9 rs1799853 C__25625805_10 
CYP2C9 rs1057910 C__27104892_10 
CYP2D6 rs35742686 C__32407232_50 
CYP2D6 rs3892097 C__27102431_D0 
CYP2D6 rs5030656 C__32407229_60 
CYP2D6 rs1065852 C__11484460_40 
CYP2D6 rs28371725 C__34816116_20 
CYP3A4 rs35599367 C__59013445_10 
CYP3A5 rs776746 C__26201809_30 
CYP4F2 rs2108622 C__16179493_40 
DPYD rs67376798 C__27530948_10 
FXR rs56163822 C__25598386_10 
LXRα rs2279238 C__15967384_10 
POR rs1057868 C___8890131_30 
PXR rs2276707 C__15882324_10 
SLCO1B1 rs2306283 C___1901697_20 
SLCO1B1 rs4149056 C__30633906_10 
SLCO1B3 rs7311358 C__25765587_40 
SLCO2B1 rs12422149 C___3101331_10 
TPMT rs1800460 C__30634116_20 
TPMT rs1142345 C_____19567_20 
VDR rs11568820 C___2880808_10 
VDR rs4516035 C___2880805_10 
VKORC1 rs9923231 C__30403261_20 
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Statistical analysis 
 
 Analyses were performed using the software R (14) and GraphPad Prism 6 
(La Jolla, USA). Differences in the proportion of possibly deleterious variants 
between common, low frequency, and rare or novel variant groups was assessed 
using a Chi-squared test (statistical significance, P value <0.05). Pearson correlation 
coefficient was used to determine association between our study allele frequencies 
with those reported in the ExAC database (statistical significance, two-tailed P value 
<0.05). 
 
  
 
 172 
References: 
1. Johansen CT, Dube JB, Loyzer MN, MacDonald A, Carter DE, McIntyre AD, 
et al. LipidSeq: a next-generation clinical resequencing panel for monogenic 
dyslipidemias. Journal of lipid research. 2014;55(4):765-72. 
2. Andrews S. FastQC: a quality control tool for high throughput sequence data. 
2010 [Available from: 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc. 
3. Guo Y, Ye F, Sheng Q, Clark T, Samuels DC. Three-stage quality control 
strategies for DNA re-sequencing data. Briefings in Bioinformatics. 2013. 
4. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic 
variants from high-throughput sequencing data. Nucleic Acids Res. 
2010;38(16):e164. 
5. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general 
framework for estimating the relative pathogenicity of human genetic variants. 
Nat Genet. 2014;46(3):310-5. 
6. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nature 
protocols. 2009;4(7):1073-81. 
7. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
et al. A method and server for predicting damaging missense mutations. Nature 
methods. 2010;7(4):248-9. 
8. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. 
Identification of functionally variant MDR1 alleles among European 
Americans and African Americans. Clinical pharmacology and therapeutics. 
2001;70(2):189-99. 
9. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A 
novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black 
African population: association with diminished debrisoquine hydroxylase 
activity. British journal of clinical pharmacology. 1996;42(6):713-9. 
10. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: 
identification of multiple allelic variants associated with altered transport 
activity among European- and African-Americans. The Journal of biological 
chemistry. 2001;276(38):35669-75. 
11. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, 
Mokrab Y, et al. Identification of novel functional organic anion-transporting 
polypeptide 1B3 polymorphisms and assessment of substrate specificity. 
Pharmacogenetics and genomics. 2011;21(3):103-14. 
12. Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid 
detection of CYP2D6 null alleles by long distance- and multiplex-polymerase 
chain reaction. Pharmacogenetics. 1996;6(5):417-21. 
 
 173 
13. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, et al. 
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal 
expression, polymorphisms and sulfasalazine as an in vivo probe. 
Pharmacogenetics and genomics. 2008;18(5):439-48. 
14. R Core Team. R: A Language and Environment for Statistical Computing. 
Vienna, Austria: R Foundation for Statistical Computing; 2015 [Available 
from: https://www.r-project.org/. 
 
 174 
Appendix E 
Figure S1. Mean Phred quality score for sequencing reads per read length. Yellow arrow indicates Phred base quality score ≥30 (99.9% 
sequencing accuracy) up until the 150bp read position. Base quality declines for sequencing reads that were more than 150bp in length, 
resulting in a mean ≥30 Phred quality score of 62.6% (Run 1), 65.1% (Run 2), and 63.2% (Run 3). 
 
 
 
 175 
Figure S2. Frequency distribution of the percentage of guanine and cytosine nucleotides per sequenced read in 48 subjects. Arrows 
indicate the five samples with aberrantly higher GC content. 
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Figure S3. Mean (±SD) depth of coverage (DOC) across the targeted sequence for CES1, CBR1, CYP1A2 and showing 
the inaccessible target regions. 
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Figure S4. Data represented a mean subject DOC (±SD) across target sequence. Inter-subject and intra-subject variability 
of DOC across the target sequence in the validation cohort (n = 48). Matching coloured arrows indicate the five samples 
with aberrantly higher GC content. (‡) 1 sample repeated (PGST395). 
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Figure S5. Similarity of observed minor allele frequencies (MAF) in relation to the 
reported MAF in 1000 Genomes Project (1000G) and Exome Aggregation 
Consortium (ExAC) datasets.  
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Figure S6. Rare or novel variations had greater proportion of deleterious in silico prediction scores (n = 245). 
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Figure S7. Zygosity of the potentially deleterious variants (CADD scaled score greater than 20) per subject (n = 245), showing there 
were more heterozygous variants per subject compared to homozygous. Single nucleotide variants (SNV) found in Cytochrome P450 
(CYP) enzymes (CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2J2, CYP3A4, CYP3A5, and 
CYP4F2 ) were highlighted in yellow.  
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Figure S8. Number of Clinical Pharmacogenetics Implementation Consortium (CPIC) “Level 1A/1B” variants (categorized as having 
strong supporting evidence for affecting drug efficacy/response as well as specific prescribing recommendations 
https://cpicpgx.org/alleles/) found in 245 subjects separated by zygosity. 
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Figure S9. Histogram of the GSTM1 and GSTT1 gene coverage as a fraction total subject coverage in 45 subjects (excluding 3 
subjects with aberrant GC content; PGST362, PGST357, PGON131).  
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Figure S10. Mean (±SD) depth-of-coverage (DOC) across the targeted sequence of select 
genes (n = 24; from Sequencing Run 1 and Run 2). Vertical lines represent (red) CPIC 
level 1A/1B clinically actionable variant, and (green) NGS identified variants with scaled 
CADD score greater than 20, along with their minor allele frequencies (MAF) if found in 
our cohort (70 subjects). Possibly deleterious variants in CYP2D6 (●). 
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